<SEC-DOCUMENT>0001213900-19-027238.txt : 20191231
<SEC-HEADER>0001213900-19-027238.hdr.sgml : 20191231
<ACCEPTANCE-DATETIME>20191231100333
ACCESSION NUMBER:		0001213900-19-027238
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20191230
FILED AS OF DATE:		20191231
DATE AS OF CHANGE:		20191231

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	CRUDE PETROLEUM & NATURAL GAS [1311]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A6
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30314
		FILM NUMBER:		191318295

	BUSINESS ADDRESS:	
		STREET 1:		47 AVENUE ROAD
		STREET 2:		SUITE 200
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5R 2G3
		BUSINESS PHONE:		416-929-1806

	MAIL ADDRESS:	
		STREET 1:		47 AVENUE ROAD
		STREET 2:		SUITE 200
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M5R 2G3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k123019a_portagebiotech.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">For the month of December 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Commission File Number 0-30314</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>47 Avenue Rd., Suite 200, Toronto, Ontario,
Canada M5R 2G3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Indicate by check mark whether the
registrant files or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Form 20-F&nbsp;&#9746;&nbsp;&nbsp;Form
40-F&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Indicate by check mark whether the registrant
by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to
Rule 12g3-2(b) under the Securities Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Yes&nbsp;&#9744;&nbsp;&nbsp;No&nbsp;&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">If &ldquo;Yes&rdquo; is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- ______________.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 10%"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; width: 88%"><FONT STYLE="font-size: 10pt"><B>Exhibit</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f6k123019aex99-1_portage.htm"><FONT STYLE="font-size: 10pt">Consolidated Interim Financial Statements for the three months ended June 30, 2019. Unaudited - Prepared by Management as at December 30, 2019.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="f6k123019aex99-2_portage.htm"><FONT STYLE="font-size: 10pt">Management&rsquo;s Discussion and Analysis for the three months ended June 30, 2019. Prepared by Management as at December 30, 2019.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; background-color: white"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">Dated: December 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">PORTAGE BIOTECH INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="width: 37%; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kam Shah</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kam Shah</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0; background-color: white">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0pt; background-color: white">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>f6k123019aex99-1_portage.htm
<DESCRIPTION>CONSOLIDATED INTERIM FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED JUNE 30, 2019. UNAUDITED - PREPARED BY MANAGEMENT AS AT DECEMBER 30, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>Consolidated Interim Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">For the three months ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>(Unaudited &ndash; Prepared by Management)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>(US Dollars)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Interim Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">For the Three Months Ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 89%; layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Index</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="width: 10%; layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>pages</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notice to Reader</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Interim Statements of Financial Position</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Interim Statements of Operations and Other Comprehensive Income</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif">F-4</TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Interim Statements of Changes in Shareholders&rsquo; Equity</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Interim Statements of Cash Flows</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="layout-grid-mode: line; font: 10pt Times New Roman, Times, Serif"><A HREF="#portage_99-1_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Interim Financial Statements</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; text-align: center; font: 10pt Times New Roman, Times, Serif">F-<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7
    - F-20</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_001"></A><B>NOTICE TO READER OF CONSOLIDATED INTERIM FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated interim financial statements for Portage Biotech
Inc. comprised of the consolidated interim statements of financial position as at June 30, 2019 and for the year ended March 31,
2019, and the consolidated interim statement of operations, statement of changes in equity and cash flows for the three-month period
ended June 30, 2019 and are the responsibility of the Company&rsquo;s management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated interim financial statements have been prepared
by management and include the selection of appropriate accounting principles, judgments and estimates necessary to prepare these
consolidated interim financial statements in accordance with International Financial Reporting Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The consolidated interim financial statements have not been
reviewed by the Company&rsquo;s independent external auditors, Marcum LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; layout-grid-mode: line; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;</FONT></TD>
    <TD STYLE="width: 50%; layout-grid-mode: line; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;signed&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kam Shah CPA,C.A., Director</FONT></TD>
    <TD STYLE="layout-grid-mode: line; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Walters MD, Director</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.95pt 0pt 0">December 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 35.95pt 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_002"></A><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Interim Statements of Financial Position</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(US Dollars)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Unaudited &ndash; see Notice to Reader
dated December 30, 2019)</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">As at ,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR>
 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">March 31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">(Audited)</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">in 000$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Assets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Current</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,187</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">4</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">429</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 16.2pt">Investments in marketable equity securities</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">6</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">88</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">103</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">5,704</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">6,551</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Long-term assets</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Long term portion of other receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">4</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">45</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment in associate</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">7</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,164</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,207</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Investment in private companies</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">9</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5,200</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5,200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Goodwill</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">10</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">43,324</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,324</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 16.2pt">In process research and development</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">10</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">117,388</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">117,388</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">172,825</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,715</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Liabilities and Equity</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Current liabilities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accrued liabilities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,411</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,107</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Unsecured notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">11</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">665</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">663</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 16.2pt">Warrant liability</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">11</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2100</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,794</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Non-current liabilities</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Unsecured notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">11</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,000</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 16.2pt">Deferred tax liability</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">10</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">20,364</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">20,364</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">23,364</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,364</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">25,464</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">25,158</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Shareholders&rsquo; Equity</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Capital stock</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">12</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">116,237</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">116,237</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock option reserve</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">13</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">329</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">324</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Accumulated other comprehensive income</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">67</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">82</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(18,411</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,969</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total equity attributable to owners of the Company</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">98,222</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">99,674</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Non-controlling interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt">20</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">49,139</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">48,883</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">147,361</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">148,557</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total liabilities and equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">172,825</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">173,715</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Commitments and Contingent Liabilities (Note 15)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 18%; layout-grid-mode: line; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>On behalf of the Board&nbsp;</B></FONT></TD>
    <TD STYLE="width: 18%; border-bottom: Black 1.5pt solid; layout-grid-mode: line; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Kam Shah&rdquo;</FONT></TD>
    <TD STYLE="width: 10%; layout-grid-mode: line; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT>&nbsp;</TD>
    <TD STYLE="width: 18%; border-bottom: Black 1.5pt solid; layout-grid-mode: line; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;Ian Walters&rdquo;</FONT></TD>
    <TD STYLE="width: 36%; layout-grid-mode: line; white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="layout-grid-mode: line; text-align: justify; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(signed)</FONT></TD>
    <TD STYLE="layout-grid-mode: line; text-align: justify; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="layout-grid-mode: line; white-space: nowrap; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(signed)</FONT></TD>
    <TD STYLE="layout-grid-mode: line; white-space: nowrap">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of these consolidated
interim financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_003"></A><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Interim Statements of Operations and Other Comprehensive
Loss</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(US Dollars)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Unaudited &ndash; see Notice to Reader
dated December 30, 2019)</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>



<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Three months ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Note</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">in 000$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Expenses</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 11%">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">433</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">61</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Consulting fees</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">16</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,076</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.25in">Professional fees</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">243</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.25in">Other operating costs</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">46</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Loss from operations</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,798</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(164</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">share of losses in associates accounted for using equity method</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(43</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.25in">interest income (expense)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(95</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net (loss)</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,936</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(219</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Other comprehensive income</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Unrealized (loss) gain on Investment in Biohaven</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(15</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Total comprehensive (loss) for period</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,951</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(192</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net ( loss) attributable to :</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Owners of the Company</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,442</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(219</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.25in">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(494</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,936</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Comprehensive Profit(loss) attributable to :</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Owners of the Company</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,456</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(192</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.25in">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(494</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,950</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(192</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.125in">(loss) per share (Actual)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.25in">Basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(0.00</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.125in">Weighted average shares outstanding</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.25in">Basic and diluted</TD><TD>&nbsp;</TD>
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,085,790</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of these consolidated
interim financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_004"></A><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Interim Statements of Changes in Shareholders&rsquo;
Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For The Three Months Ended June 30, 2019</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(US Dollars)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Unaudited &ndash; see Notice to Reader
dated December 30, 2019)</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital Stock</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Option Reserve</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Accumulated other comprehensive income</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retained earnings (Accumulated Deficit)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Equity Attributable to Owners of Company</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-controlling Interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Equity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000&rsquo;</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In &lsquo;000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 20%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balance, April 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">280,720</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">23,654</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">32</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">(14,334</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">9,619</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 7%; text-align: right">9,619</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Unrealized gain on investment in Biohaven</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Net loss for period</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Balance, June 30, 2018</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">283,959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">23,654</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">276</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">59</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(14,553</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,922</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,436</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balance, April 1, 2019</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,085,790</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">116,237</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">324</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">82</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(16,969</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">99,674</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">48,883</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">148,557</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">Share based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">5</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">750</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">755</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Unrealized (loss) on investment in Biohaven</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(15</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(15</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Net loss for period</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,442</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,442</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(494</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,936</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Balance, June 30, 2019</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,085,790</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">116,237</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">329</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">67</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(18,411</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">98,972</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">48,389</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">147,361</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of these consolidated
interim financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_005"></A><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Consolidated Interim Statements of Cash Flows</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(US Dollars)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Unaudited &ndash; see Notice to Reader
dated December 30, 2019)</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">For the three months ended June 30,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2,019</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,018</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">in 000$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Cash flows from operating activities</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Net loss for the period</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(1,936</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(219</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Adjustments for non-cash items:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Value of shares and options expensed as consulting fee</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">755</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Increase in warrant liability charged to interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 16.2pt">Share of losses in associate</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">43</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">69</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 16.2pt">Prepaid expenses and other receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(147</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(16</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 16.2pt">Accounts payable and accrued liabilities</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">306</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(30</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(979</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(185</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">(Decrease) in cash during period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(979</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(185</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Cash at beginning of period</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">6,166</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,520</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cash at end of period</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5,187</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">7,335</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Supplemental disclosure of non-cash investing activity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Unrealized (loss) gain on Investment in Biohaven</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>The accompanying notes are an integral part of these consolidated
interim financial statements.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-1_006"></A><B>Portage Biotech Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Notes to Consolidated Interim Financial Statements</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(US Dollars)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>June 30, 2019 and 2018</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">(Unaudited &ndash; see Notice to Reader
dated December 30, 2019)</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: left">NATURE OF OPERATIONS AND GOING CONCERN</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Portage Biotech Inc. (the &ldquo;Company&rdquo;) is
incorporated in the British Virgin Islands (&ldquo;BVI&rdquo;) with its registered office located at FH Chambers, P.O. Box 4649,
Road Town, Tortola, BVI. Its Toronto agent, Portage Services Ltd., is located at 47 Avenue Road, Suite 200, Toronto, Ontario, M5R
2G3, Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is a reporting issuer with the Ontario
Securities Commission on the Canadian Stock Exchange under the symbol PBT-U and US Securities and Exchange Commission on the OTC
market under the symbol PTGEF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is engaged in the business of researching
and developing pharmaceutical and biotechnology products through to clinical &ldquo;proof of concept&rdquo; with an initial focus
on unmet clinical needs. Following proof of concept, the Company seeks to sell or license the products to large pharmaceutical
companies for further development and commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="background-color: white">The Company&rsquo;s
existing subsidiaries are in the pre-clinical stage, and as such no revenue has been generated from their operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD><B>BASIS OF PRESENTATION </B></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: left">Statement of Compliance and Basis of presentation</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">These consolidated Interim financial statements have
been prepared in accordance with the International Financial Reporting Standards (&ldquo;IFRS&rdquo;) issued by the International
Accounting Standards Board (&ldquo;IASB&rdquo;), IAS 34 <I>Interim Financial Reporting</I> and interpretations of the International
Financial Reporting Interpretations Committee. These consolidated interim financial statements do not include all of the information
required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements
of the Company for the year ended March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">These consolidated interim financial statements have
been prepared on a historical cost basis except for items disclosed herein at fair value. In addition, these consolidated interim
financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
Company has only one material operating segment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">These
consolidated financial statements were approved and authorized for issue by the Audit Committee and Board of Directors on December
30, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>2.</B></TD><TD><B>BASIS OF PRESENTATION - continued</B></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b)</TD><TD STYLE="text-align: left">Consolidation</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">The
consolidated financial statements include the accounts of the Company and,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">a.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Portage Services Ltd., a wholly owned subsidiary incorporated in
Ontario on January 31, 2011.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">b.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Portage Pharmaceuticals Ltd. (&ldquo;PPL&rdquo;) a wholly owned
subsidiary resulting from a merger on July 23, 2013 and is incorporated under the laws of the British Virgin Islands, as a BVI
business company.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">c.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">EyGen Limited, (&ldquo;EyGen&rdquo;) which is a wholly owned subsidiary
of PPL, was incorporated on September 20, 2016 under the laws of the BVI.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">d.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">SalvaRx Limited (&ldquo;SalvaRx&rdquo;), a wholly owned subsidiary,
incorporated on May 6 2015 in the British Virgin Islands.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">e.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Portage Glasgow Ltd (&ldquo;PGL&rdquo;), a 65% subsidiary of PPL,
incorporated in Glasgow, Scotland.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">f.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">IOX Therapeutics Ltd (&ldquo;IOX&rdquo;), a United Kingdom based
immune-oncology company, a 60.49% subsidiary incorporated in the United Kingdom on February 10, 2015.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">g.</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Saugatuck, a 70% owned subsidiary incorporated in the British Virgin
Islands.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">All
inter-company balances and transactions have been eliminated on consolidation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Non-controlling
interest in the equity of a subsidiary is accounted for and reported as a component of stockholders&rsquo; equity. Non-controlling
interest represents the 39.51% shareholder ownership interest in IOX and the 30% shareholder ownership interest in Saugatuck which
are consolidated by the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left">Functional and presentation currency</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company&rsquo;s functional and presentation currency
is US Dollar.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><B>(d)</B></TD><TD><B>Use of Estimates and judgments</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The preparation of the consolidated financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting
policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Estimates and underlying assumptions are reviewed on
an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any
future periods affected. Significant areas where estimation uncertainty and critical judgments are applied include valuation of
financial instruments, research and development costs, fair value used for acquisition, assessment of impairment in goodwill and
other intangible assets and measurement of share- based compensation, in the current and prior periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>3.</B></TD><TD><B>SIGNIFICANT ACCOUNTING POLICIES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The accounting policies are set out in Note 3 to the
fiscal 2019 audited consolidated financial statements. These policies have been applied consistently to all periods presented in
these consolidated interim financial statements,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">New accounting standards, interpretations
and amendments</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">During
the current interim period the company adopted the requirements of IFRS 16 in respect to lease obligations. However, management
determined that it had no leases to which the standard applied, and therefore there was no impact on its financial statements.
The Company is also unaware of any applicable but not-yet-adopted standards that are expected to materially affect the financial
statements of future periods.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: left">PREPAID EXPENSES AND OTHER RECEIVABLE</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Prepaid expenses</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">15</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">19</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">R &amp; D credits</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">357</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Other receivable</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">57</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">55</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">429</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">282</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">In
October 2016, the Company&rsquo;s wholly owned subsidiary, PPL agreed to a settlement of $120,000 for a claim made against a supplier.
As of June 30, 2019, the Company received $63,750. The remaining balance is payable in five annual instalments of $11,250. Accordingly,
$11,250 is classified as a current asset within other receivables and the non-current portion of $45,000 is classified as a long-term
asset ($45,000 classified as a long-term asset and $11,250 classified as a current asset as at March 31, 2019).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>5.</B></TD><TD><B>CONVERTIBLE NOTE RECEIVABLE </B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">A<B>s</B> of June 30, 2019, the Company invested $1.9
million in a convertible note (the &ldquo;Notes&rdquo;) issued by IOX in U.S. dollars. The Notes carry interest at 7% accruing
daily and mature within twelve months of their issuance. The Company can convert the notes and accrued interest into ordinary shares
of IOX at any time before maturity at &pound;120 per share. There is an automatic conversion on a qualifying event, being IOX raising
$2 million or a sale of the Company per the agreement. Conversion price will be the price at which the money was raised discounted
by 25%. IOX has the right to repay the Notes together with accrued interest at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">As
a result of the SalvaRx Acquisition in fiscal 2019, IOX became a subsidiary of the Company and in accordance with IFRS 3 &ndash;
Business combinations, the fair value, including interest receivable, of the Notes were effectively settled upon the business combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: left">INVESTMENT IN MARKETABLE EQUITY SECURITIES</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Investment comprises 2,000 shares in Biohaven Pharmaceutical
Holding Company Limited, (Biohaven) a public company listed on NYSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company currently accounts for its investment
in Biohaven as a financial asset classified as FVTOCI</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As at June 30, 2019, the shares were valued at the
quoted market price of Biohaven share of $43.79 and the difference between the carrying value and the fair value being unrealized
loss of $15,360 is included in the other comprehensive income.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
following table is a rollforward of the investment in Biohaven</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended June&nbsp;30,<BR>
 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year <BR>
ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance at Beginning of period</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">103</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">53</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Unrealized (loss) gain on investment</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(15</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance at end of period</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">88</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">103</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">7.</TD><TD STYLE="text-align: justify">INVESTMENT IN ASSOCIATE</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Details
of the Company&rsquo;s associate as of June 30, 2019 and March 31, 2019 are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Principal Activity</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Place of Incorporation and principal place of business</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Voting rights held as at<BR> June&nbsp;30, 2019<BR> and March&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Associate:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 59%; text-align: left">Stimunity S.A.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Biotechnology</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 12%; text-align: center">Paris, France</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 12%; text-align: right">36.5</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The abovementioned associate is accounted for using
the equity method in these consolidated financial statements.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
following table is a rollforward of the investment Stimunity S.A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended<BR>
 June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year<BR>
 ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-indent: -0.1in; padding-left: 0.1in">Balance at Beginning of period</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">1,207</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">681</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Additional investment</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">688</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Share of losses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(43</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(162</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,164</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,207</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Under
the shareholders agreement, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the
event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock
options under a merger plan or for an acquisition, or (ii) the right to vote against any (a) issuances of additional securities
that would call for the Company to waive its preferential subscription right or (b) any dilutive issuance.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">As
at June 30, 2019, the Company evaluated the progress achieved by Stimunity and has determined that there was no evidence of any
impairment in the value of this investment and as a result no adjustment was considered necessary in its carrying value.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: left">INVESTMENT IN PGL</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
Company&rsquo;s wholly owned subsidiary, PPL holds 650 ordinary shares of Portage Glasgow Ltd. (PGL), at &pound;0.01 per share
for a total consideration of &pound;6.50 ($9.11). PPL&rsquo;s ownership comprised 65% of the issued ordinary shares in PGL. PPL&rsquo;s
Chief Executive Officer (&ldquo;CEO&rdquo;) is also the chairman of the board of directors of PGL which currently consists of two
persons. PGL is therefore considered a subsidiary and consolidated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">As
per the terms of a Convertible Loan Agreement dated January 31, 2018 signed with PGL, PPL has committed to provide PGL with an
unsecured convertible loan facility up to &pound;1 million ($1.4 million) with a minimum drawdown of &pound;50,000 ($70,075) and
maximum drawdown of &pound;250,000 ($350,375) during any three-month period. Interest will be at 7% accruing on a monthly basis
and the facility is repayable within nine years from the date of the agreement. The outstanding loan with accrued interest can
be converted into ordinary shares of PGL to be priced at between &pound;9,000 per share and &pound;5,000 per share depending on
the conversion date being within one year to eight years. However, completion of an eligible fundraising by PGL, being &pound;5
million ($7 million) at a pre-money valuation of minimum &pound;10 million ($14 million), will require the loan to be mandatorily
converted as per the terms of conversion described above. The total drawdown as at June 30, 2019 amounted to $174,299 (As at March
31, 2019 amounted to $45,378).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: left">INVESTMENT IN PRIVATE COMPANIES</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">As at</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June&nbsp;30,<BR> 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">March&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left">Sentien Biotechnologies Inc.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">700</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">700</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Intensity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">5,200</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5,200</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Sentien</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">In
August 2015, the Company acquired 210,210 shares of Series A preferred stock in Sentien (&ldquo;Preferred Stock&rdquo;), a Medford,
MA based private company for $700,000 of cash. The Preferred Stock is fully convertible into equal number of common shares. The
Company&rsquo;s holdings represent 5.06% of the equity of Sentien on a fully diluted basis as at June 30, 2019 and March 31, 2019,
respectively. The investment in Sentien has been irrevocably designated as a financial asset recorded at fair value with gains
and losses recorded through OCI. In accordance with the guidance in IFRS 9 regarding when cost may be the best estimate of fair
value, Sentien is recorded at cost.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">Intensity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">In
connection with the SalvaRx Acquisition in the fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a clinical
stage biotechnology company, for 1 million shares, or a 7.5% equity interest in Intensity. The investment was recorded at fair
value (which approximates cost) at the acquisition date. The investment in Intensity has been irrevocably designated as a financial
asset recorded at fair value with gains and losses recorded through OCI. The fair value of the asset is determined by considering
other comparable equity funding transactions by Intensity with unrelated investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">As
at June 30, 2019 and March 31, 2019, the Company has determined that there was no evidence of any impairment in the value of the
above investments and as a result no adjustment was considered necessary in their carrying values.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: left">GOODWILL, IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: left; text-indent: -21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Three months ended June 30,&nbsp;2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Year ended March 31,&nbsp;2019</TD><TD STYLE="padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IPRD</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">DTL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Goodwill</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IPRD</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">DTL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">Balance at Beginning of period</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">43,324</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">117,388</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">(20,364</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0.125in; text-indent: -0.125in">On acquisition of Salvarx Ltd</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,324</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">117,388</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(20,364</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-left: 0.125in; text-indent: -0.125in">amortization</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in">Impairment</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; padding-left: 0.125in; text-indent: -0.125in">Balance at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">43,324</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">117,388</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(20,364</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">43,324</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">117,388</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(20,364</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: left; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Goodwill
related to acquisition of Salvarx Ltd in January 2019. The management evaluated the value of the underlying net assets as at June
30, 2019 and concluded that here was no impairment in goodwill.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">In
process research and development (IPRD) related to the value of pre-clinical research work carried out at IOX and Saugatuck prior
to their acquisition in January 2019. The valuation was carried out by an independent valuator using discounted cash flow model
(DCF). The management has evaluated the continuing work at these entities and updated the DCF model as at June 30, 2019 and concluded
that IPRD required no adjustment. IPRD will be amortized once a commercial viability of the products is established or written
off if the projects are abandoned.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: left">GOODWILL, IN PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY &ndash; continued</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: left; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Deferred
tax (DTL) related to IPRD at IOX which is subject to tax in UK. As at June 30, 2019, there was no change in the amount and status
of IOX IPRD and as a result, no changes were considered necessary in the amount of deferred tax. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: left">UNSECURED NOTES PAYABLE AND WARRANTS</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: left; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Following
is a rollforward of the notes payable and the warrant liability:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">EyGen</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IOX</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">SalvaRX</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold">Balance, April 1, 2019</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">193</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">100</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">3,370</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">3,663</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt">Interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Balance, June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">195</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">100</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,370</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,665</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">PPL</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">EyGen</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">IOX</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">SalvaRX</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Balance, April 1, 2018</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">210</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">23</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">233</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Repayment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(25</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(50</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Interest</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Fair value on acquisition</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">100</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,370</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,470</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">Balance, March 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">193</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">100</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,370</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,663</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 14.2pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>Warrant liability</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">EyGen</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">In 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font-weight: bold; padding-bottom: 1.5pt">Balance, April 1, 2019</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">22</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">2</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">24</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt">Balance, June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">22</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">24</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">PPL</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">EyGen</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; padding-bottom: 1.5pt">Balance, April 1, 2018</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">22</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">2</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">24</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt">Balance, March 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">24</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 14.2pt; text-indent: -14.2pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><B>PPL and EyGen Loan Notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">The Unsecured Notes issued by PPL and EyGen bear interest at
7% per annum, payable annually on the issuance date. The Unsecured Notes are not redeemable by the Company prior to maturity. In
conjunction with the issuance of the Unsecured Notes, the note holders were also issued a warrant to subscribe for $7,500 new PPL
or Eygen ordinary shares for every $10,000 of principal issued, respectively, provided that a certain qualifying event occurs within
the three years of issuance. The warrants are only exercisable on a qualifying event and the exercise price of the warrant will
be based on the price of equity shares determined by the qualifying event and the year in which it takes place. The warrants have
a three-year term. Given that there was an obligation to issue a variable number of shares, the warrants were classified as financial
liabilities and recorded at fair value of $24,000 in warrant liabilities in the accompanying consolidated balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">11.</TD><TD STYLE="text-align: left">UNSECURED NOTES PAYABLE AND WARRANTS - continued</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>SalvaRx loan notes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0in 0.5in">In connection with the SalvaRx Acquistion in January 2019, the
Company assumed $3.96 million of principal in unsecured notes issued by SalvaRx due on March 2, 2021 (or a qualifying event), that
bear interest of 7% (the &ldquo;SalvaRx Notes&rdquo;). As the SalvaRx Acquisition was a qualifying event, the unsecured notes became
due upon the acquisition. On January 8, 2019, the acquisition date, the fair value of the SalvaRx Notes was determined to be $3.4
million using a 12.5% market interest rate to discount all payments of principal and interest due to the holders of such notes
through the date of maturity. The holders of the SalvaRx Notes received $7,500 of warrants in respect of each $10,000 of principal
issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The warrants vest in the event of a qualifying transaction and
are exercisable at a 30% discount to the implied valuation of SalvaRx. On the Acquisition Date, the fair value of warrants, which
are included in non-controlling interest, was determined to be $2.5 million using the Black Scholes Model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>IOX loan notes </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0.5in; text-align: left">In connection with the SalvaRx
Acquistion in January 2019, the Company assumed $2.0 million of 7% convertible notes issued by IOX, a wholly owned subsidiary of
SalvaRx (the &ldquo;Convertible Notes&rdquo;), of which the Company holds $1.9 million. As a result of the SalvaRx Acquisition,
IOX has become a subsidiary of the Company during the year ended March 31, 2019. In accordance with IFRS 3 &ndash; Business combinations,
the fair value notes payable was effectively settled against the note receivable (see Note 5). The remaining Convertible Notes
issued to a third party, including the conversion option, are recorded at a fair value of $0.1 million. In each of March 2019 and
December 2019, $0.05 million of loan mature. The holders of the Convertible Notes can convert the notes and accrued interest into
ordinary shares of IOX at any time before maturity at &pound;120 per share. There is an automatic conversion in the event IOX raises
$2 million, and the conversion price will be determined on the timing of the capital raise and the price at which the money was
raised. IOX has right to repay the Convertible Notes together with interest at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.85pt 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>12.</B></TD><TD><B>CAPITAL STOCK</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: left">Authorized<B>: </B>Unlimited number of common shares</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">(b)</FONT></TD><TD><FONT STYLE="font-weight: normal">Issued: There was no change in the number and amount of issued and outstanding common shares
during the three months ended June 30, 2019, which remained at 1,085,789,986 and $116,236,663 respectively as June 30, 2019 and
March 31, 2019.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">(c)</FONT></TD><TD><FONT STYLE="font-weight: normal">As at June 30, 2019 and March 31, 2019, the Company had no active Consultant Stock Compensation
Plan.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -21.8pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">13.</TD><TD STYLE="text-align: left">STOCK OPTION RESERVE</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">(a)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">The following table provides the activity for the Company&rsquo;s
stock option reserve:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock option Reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock option Reserve</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-indent: -0.1in; padding-left: 0.1in">Balance, beginning of Period</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,475</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">324</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">267</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Value of IOX options relating to pre-acquisition services</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Stock based compensation expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">750</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">5</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">57</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Balance, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">9,225</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">329</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,475</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">324</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-weight: normal">(b)</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">The movements in Options issued were:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PBI 2013 Option Plan</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PPL Option Plan<BR>
 (Subsidiary Plan)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">iOx Option Plan<BR>
 (Subsidiary Plan)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year <BR>
ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year <BR>
ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">Year<BR>
 ended March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Balance, at beginning of period</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">595,842</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,845,842</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">57,258</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">47,917</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">2,599</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Acquired form Salvarx Acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,599</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Granted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,341</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Cancelled</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,250,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance, at end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">595,842</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">595,842</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">57,258</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">57,258</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,599</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,599</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Exercisable, end of period</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">595,842</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">595,842</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">55,390</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">50,253</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,802</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,728</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">the Board discontinued the 2013 Option Plan in the fiscal
2019. No additional shares will be issued under this plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: left">Following are the weighted average exercise price and the remaining contractual life for outstanding options by plan:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -14.15pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">PBI 2013 Option Plan</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">PPL Option Plan<BR>
 (Subsidiary Plan)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">IOX Option Plan<BR>
 (Subsidiary Plan)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 June&nbsp;30,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at<BR>
 March&nbsp;31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Weighted average exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">0.15</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.83</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">152.74</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">152.84</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Weighted average remaining contractual life (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.72</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.38</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1.63</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.91</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.10</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -14.15pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left"><FONT STYLE="font-weight: normal">The
options can be exercised at any time after vesting within the exercise period in accordance with the applicable option agreement.
The exercise price was more than the market price on the date of the grants for all options outstanding as at June 30, 2019 and
March 31, 2019. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">14.</TD><TD STYLE="text-align: left">LOSS PER SHARE</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Three months ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>Numerator</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss attributable to owners of the Company ( in 000&rsquo;$)</TD><TD STYLE="width: 1%; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,442</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Denominator (in 000&rsquo;)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Weighted average number of shares - Basic</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,085,790</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">280,720</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Diluted effect of average number of options</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">596</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,846</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Weighted average number of shares - Diluted</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,086,386</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282,566</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Basic and diluted (loss) per share (Actual)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.00</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">(0.00</TD><TD STYLE="font-weight: bold; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Inclusion of the
options in the computation of diluted loss per share would have an anti-dilutive effect on the loss per share and are therefore
excluded from the computation. Consequently, there is no difference between loss per share and diluted loss per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>15.</B></TD><TD><B>COMMITMENTS AND CONTINGENT LIABILITIES</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD>Under the terms of a License Agreement dated January 25, 2013, PPL is required to reimburse to the Licensor, Trojan Technologies
Limited (&ldquo;Trojan&rdquo;), 50% of all maintenance costs of the US Patent #7,968,512 and to pay royalties of 3% on Net Receipts
from sales of the Licensed Product and 5% on Net Receipts from third parties in respect of development or other exploitation of
Licensed Intellectual Property and/or Licensed Products up to a maximum of $30 million. As at June 30, 2019, no royalties have
been earned and maintenance fees are insignificant, therefore no payments have been made to Trojan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD>The Company is committed to invest approximately &euro;1.5 million ($1.9 million) in Stimunity upon Stimunity&rsquo;s achievement
of certain agreed milestones. As at March 31, 2019, the Company made an additional discretionary investment of &euro;600,129 ($688,359)
toward the commitment. As at June 30, 2019, agreed milestones were not yet reached and hence no further payment under the agreement
was due.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD>PPL is committed to provide a loan facility to PGL of up to &pound;1 million ($1.4 million) and studentship grants to the University
of Glasgow of &pound;22,279 ($31,224) in equal instalments over the next two years. One instalment of $15,606 was made in 2018
and 2019 instalment of $15,606 was accrued but not paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD>SalvaRx has an obligation to make further capital contribution of &euro;0.3 million ($0.3 million) in Nekonal once certain
development milestones have been achieved (see (e) below).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in"><FONT STYLE="font-style: normal">(e)</FONT></TD><TD><FONT STYLE="font-style: normal">SalvaRx and Nekonal are currently in disagreement regarding SalvaRx&rsquo;s obligation to
make the additional equity contribution described in (d), which is due upon Nekonal&rsquo;s attainment of the defined milestone.
In April 2019, SalvaRx asserted that management of Nekonal committed a breach of duties and fraud on its minority shareholder and
Nekonal management has accused SalvaRx of breach of contract. To date, no legal proceedings have been formally commenced by either
party. Research and development efforts have been suspended pending a resolution of this matter. The Company cannot predict the
outcome of this matter and there is no assurance that a loss will not be incurred.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: -21.25pt"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>16.</B></TD><TD><B>CONSULTING FEE</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Three months ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019 in</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018 in</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">000&rsquo;$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Cash fee to management</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">$</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">133</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">45</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Cash fee to others</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">$</TD><TD STYLE="font-weight: bold; text-align: right">188</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Shares and vested Options issued to key management and directors</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">511</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Shares and vested Options issued to others</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">244</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">1,076</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">81</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">17.</TD><TD STYLE="text-align: left">RELATED PARTY TRANSACTIONS</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Board of Directors, Chairman, Chief Executive
Officer and Chief Financial Officer are key management personnel. The following subsidiaries and associates are also considered
related parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">a.</TD><TD STYLE="text-align: justify">Nokonal : One of the three directors on the Board of
Directors of Nekonal is represented by Portage. Additionally, the CEO of the Company is also the CEO of Nekonal and employees
of the Company comprise the management team of Nekonal under the service agreement for management services.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">b.</TD><TD STYLE="text-align: justify">Stimunity : One of the three directors on the Board of
Directors of Stimunity is represented by Portage</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">c.</TD><TD STYLE="text-align: justify">IOX: Two of the five directors on the Board of Directors
of IOX is represented by Portage. Additionally, Portage has an observer on the Board of IOX. The CEO of the Company is also the
CEO of IOX and employees of the Company comprise the management team of IOX.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">d.</TD><TD STYLE="text-align: justify">Saugatuck: One of the three directors on the Board of
Directors of Saugatuck is represented by Portage. Additionally, the CEO of the Company is also the CEO of Saugatuck and employees
of the Company comprise the management team of Saugatuck.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">e.</TD><TD STYLE="text-align: justify">Intensity: One of the four directors on the Board of
Directors of Intensity is represented by Portage. Additionally, the CEO of the Company is an officer and employee of Intensity.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">f.</TD><TD STYLE="text-align: justify">PGL: PPL&rsquo;s CEO is also the chairman of the two-person
board of directors of PGL.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The following are significant related party balances
and transactions other than those disclosed elsewhere in the consolidated financial statements:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD>Unsecured notes payable includes $200,000 notes issued to directors of the Company by PPL and approximately $3.2 notes issued
to directors by Salvarx Ltd.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD>Interest expense includes $59,850 interest charged on notes issued to directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Transactions between the parent company and its subsidiaries,
which are related parties, have been eliminated on consolidation and are not disclosed in this note.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: left">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
Company&rsquo;s financial instruments recognized in the balance sheet consist of the following: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">Fair
value estimates are made at a specific point in time, based on relevant market information and information about financial instruments.
These estimates are subject to and involve uncertainties and matters of significant judgment, therefore cannot be determined with
precision. Changes in assumptions could significantly affect the estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: left">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT - continued</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left"><FONT STYLE="font-weight: normal">The
following table summarizes the Company&rsquo;s financial instruments as at June 30, 2019:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As at June 30, 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid">As at March 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value to other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value to other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><U>Financial assets</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Cash and cash equivalent</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,187</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">429</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">88</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FYTPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FYTPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><U>Financial liabilities</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Accounts payable and accrued liabilities</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">1,411</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,107</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Unsecured notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,665</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,475</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">A summary of the
Company&rsquo;s risk exposures as it relates to financial instruments are reflected below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Fair value of financial
instruments</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The Company&rsquo;s
financial assets and liabilities are comprised of cash, receivables and investments in equities and private entities, accounts
payable, warrant liability and unsecured notes payable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The Company classifies
the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used
to value the instrument:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Level 1 &ndash; Values
are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Level 2 &ndash; Values
are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially
observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting
date.</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-weight: normal">&#9679;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-weight: normal">Level 3 &ndash; Values
are based on prices or valuation techniques that are not based on observable market data. Investment is classified as level 3
financial instrument.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Assessment of the
significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair
value hierarchy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Management has assessed
that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely
due to the short-term maturities of these instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.85pt"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">18.</TD><TD STYLE="text-align: left">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT -  continued</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The following methods
and assumptions were used to estimate their fair values:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Investment in Biohaven:
Fair value was based on quoted market price of $43.79 per share (Level 1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The investment in
Nekonal and the option in Nekonal has been listed at a $0 fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Investment in Sentien:
fair value of the asset is determined by considering other comparable equity funding transactions by Sentien with unrelated investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Investment in Intensity:
fair value of the asset is determined by considering other comparable equity funding transactions by Intensity with unrelated investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Unsecured notes
payable and warrant liability: The fair value is estimated using a Black Scholes model (Level 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">There have been
no transfers between levels of the fair value hierarchy for the three months ended June 30, 2019 and year ended March 31, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The Company&rsquo;s
financial instruments are exposed to certain financial risks: credit risk and liquidity risk.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Credit risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Credit risk is the
risk of loss associated with a counter-party&rsquo;s inability to fulfill its payment obligations. The credit risk is attributable
to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected on the statement
of financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Cash&ndash; Cash
is held with major international financial institutions and therefore the risk of loss is minimal.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Other receivable
&ndash; The Company is exposed to credit risk attributable to its debtor since a significant portion of this amount represents
the amount agreed on a settlement of a claim by PPL (Note 4), payable over the next six years. The debtor has so far been diligent
in paying the amounts on the due dates and PPL management will be monitoring the account on a regular basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Liquidity risk</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">Liquidity risk is
the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The Company&rsquo;s
approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities
when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company&rsquo;s
reputation. The Company holds sufficient cash to satisfy obligations under accounts payable and accruals.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">The Company monitors
its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing
in new projects. The Company believes that it has sufficient funding to finance the committed drug development work, apart from
meeting its operational needs for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">However, as a biotech
company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity
risks, including the possibility that additional financing may not be available to the Company, or that actual drug development
expenditures may exceed those planned. The current uncertainty in global markets could have an impact on the Company&rsquo;s future
ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be
available to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">19.</TD><TD STYLE="text-align: left">CAPITAL DISCLOSURES</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company considers the items included in Shareholders&rsquo;
Equity as capital. The Company had payables of approximately $ 1.4 million as at June 30, 2019 (approximately $ 1.1 million as
at March 31, 2019) and current assets of approximately $5.7 million (approximately $6.6 million as at March 31, 2019). The Company&rsquo;s
objectives when managing capital are to safeguard the Company&rsquo;s ability to continue as a going concern in order to pursue
new business opportunities and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company manages the capital structure and makes
adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain
or adjust the capital structure, the Company may attempt to issue new shares, issue new debt, acquire or dispose of assets or adjust
the amount of cash.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">As at June 30, 2019, the shareholders&rsquo; equity
was approximately $99.3 million (approximately $100 million as at March 31, 2019), $5.2 million ($ 6.2 million as at March 31,
2019) of it was held in the form of cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company is not subject to any externally imposed
capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes
to the Company&rsquo;s approach to capital management during the three months ended June 30, 2019 and 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">20.</TD><TD STYLE="text-align: left">NON-CONTROLLING INTEREST</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Three months ended June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PGL</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">SalvaRx</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IOX</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Saugatuck</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; text-indent: -0.1in; padding-left: 0.1in">Balance as of April 1, 2019</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(31</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">2,451</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">46,376</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">87</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">48,883</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">750</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">750</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss attributable to non-controlling interest</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(35</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(450</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(9</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(494</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Non-controlling interest at June 30, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">(66</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">)</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,001</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">47,126</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">78</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">49,139</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Year ended March 31, 2019</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">PGL</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salvarx</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">IOX</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Saugatuck</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">000$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Balance as of April 1, 2018</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 40%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Acquisition date fair values of non-controlling interests in subsidiaries</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">&nbsp;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">38,826</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">90</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">38,916</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">SalvaRx warrants vested upon acquisition</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Vested portion of IOX stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,364</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,364</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Stock based compensation expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,111</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,111</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss attributable to non-controlling interest</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(31</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(925</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(959</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Non-controlling interest at March 31, 2019</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(31</TD><TD STYLE="padding-bottom: 4pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,451</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">46,376</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">87</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">48,883</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">21.</TD><TD STYLE="text-align: left">EVENTS AFTER THE BALANCE SHEET DATE</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On July 11, 2019, the Company entered into an agreement
with Fast Forward Innovations Limited (&ldquo;Fast Forward&rdquo;) to purchase Intensity Holdings Limited (&ldquo;IHL&rdquo;),
a wholly owned subsidiary of Fast Forward. Portage has agreed to pay US $1,298,061 for IHL through the issuance of 12,980,610 common
shares. The sole asset of IHL consists of 288,458 shares of the private company, Intensity. This transaction will increase Portage&rsquo;s
ownership to 1,288,458 shares of Intensity (approximately 9.7% of the outstanding shares of Intensity) (see Note 9).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">On December 23, 2019, the maturity date of $3.0 million
SalvaRx Notes was extended to 2021. See Note 11.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">F-20</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>f6k123019aex99-2_portage.htm
<DESCRIPTION>MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE THREE MONTHS ENDED JUNE 30, 2019. PREPARED BY MANAGEMENT AS AT DECEMBER 30, 2019
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THREE MONTHS ENDED JUNE 30, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MANAGEMENT&rsquo;S DISCUSSION AND ANALYSIS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Prepared as at December 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><FONT STYLE="font-size: 12pt"><B>Index</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward Looking Statements</FONT></A></TD>
    <TD STYLE="width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nature of Operations and overview</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Summary of Results</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number of common shares and options</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Environment</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><A HREF="#portage_99-2_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 16.2pt; text-indent: -0.1in"><A HREF="#portage_99-2_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business Plan</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Results of Operations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liquidity and Capital Resources</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Key Contractual obligations</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Off balance sheet arrangements</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions with related third parties</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial and derivative Instruments</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of Estimates and Judgments</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Accounting Standards,Interpretations and Amedments</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Internal Controls over Financial Reporting</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.1in; text-indent: -0.1in"><A HREF="#portage_99-2_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Public securities filings</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Management Discussion and Analysis</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following discussion and analysis by
management of the financial condition and financial results for Portage Biotech Inc. for the three months ended June 30, 2019 should
be read in conjunction with the unaudited Consolidated Interim Financial Statements for the three months ended June 30, 2019 together
with the related Management Discussion and Analysis and audited consolidated financial statements for the year ended March 31,
2019 and annual report in form 20-F for the same period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A NAME="portage_99-2_001"></A>Forward looking statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">This document includes forward-looking
statements within the meaning of certain securities laws, including the &ldquo;safe harbour&rdquo; provisions of the Securities
laws. These forward-looking statements include, among others, statements with respect to our objectives, goals and strategies to
achieve those objectives and goals, as well as statements with respect to our beliefs, plans, objectives, expectations, anticipations,
estimates and intentions. The words &ldquo;may&rdquo;, &ldquo;will&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;would&rdquo;,
&ldquo;suspect&rdquo;, &ldquo;outlook&rdquo;, &ldquo;believe&rdquo;, &ldquo;plan&rdquo;, &ldquo;anticipate&rdquo;, &ldquo;estimate&rdquo;,
&ldquo;expect&rdquo;, &ldquo;intend&rdquo;, &ldquo;forecast&rdquo;, &ldquo;objective&rdquo;, &ldquo;hope&rdquo; and &ldquo;continue&rdquo;
(or the negative thereof), and words and expressions of similar import, are intended to identify forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">By their very nature, forward-looking statements
involve inherent risks and uncertainties, both general and specific, which give rise to the possibility that predictions, forecasts,
projections and other forward-looking statements will not be achieved. Certain material factors or assumptions are applied in
making forward-looking statements and actual results may differ materially from those expressed or implied in such statements.
We caution readers not to place undue reliance on these statements as a number of important factors, many of which are beyond our
control, could cause our actual results to differ materially from the beliefs, plans, objectives, expectations, anticipations,
estimates and intentions expressed in such forward-looking statements. These factors include, but are not limited to; the applicability
of patents and proprietary technology; possible patent litigation; approval of products in the Company&rsquo;s pipeline; marketing
of products; meeting projected drug development timelines and goals; product liability and insurance; dependence on strategic partnerships
and licensees; concentration of the Company&rsquo;s revenue; substantial competition and rapid technological change in the pharmaceutical
industry; the publication of negative results of clinical trials of the Company&rsquo;s products; the ability to access capital;
the ability to attract and retain key personnel; changes in government regulation or regulatory approval processes; dependence
on contract research organizations; third party reimbursement; the success of the Company&rsquo;s strategic investments; the achievement
of development goals and time frames; the possibility of shareholder dilution; market price volatility of securities; and the existence
of significant shareholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We caution that the foregoing list of important
factors that may affect future results is not exhaustive. When reviewing our forward-looking statements, investors and others should
carefully consider the foregoing factors and other uncertainties and potential events. Additional information about factors that
may cause actual results to differ materially from expectations, and about material factors or assumptions applied in making forward-looking
statements, may be found in the &ldquo;Risk Factors&rdquo; section under &ldquo;Business Environment&rdquo; and elsewhere in the
following Management&rsquo;s Discussion and Analysis of Operating Results and Financial Position for the three months ended June
30, 2019. We do not undertake to update any forward-looking statements, whether written or oral, that may be made from time to
time by us or on our behalf; such statements speak only as of the date made. The forward-looking statements included herein are
expressly qualified in their entirety by this cautionary language.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In this report the words &ldquo;us&rdquo;,
&ldquo;we&rdquo;, &ldquo;our&rdquo;, &ldquo;the Company&rdquo;, and &ldquo;Portage&rdquo; have the same meaning unless otherwise
stated and refer to Portage Biotech Inc. and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><A NAME="portage_99-2_002"></A>Nature of Operation and overview</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage Biotech Inc. (&ldquo;the Company&rdquo;)
was operating as an Ontario, Canada incorporated company, Bontan Corporation Inc. (&ldquo;Bontan&rdquo;) until July 5, 2013. On
July 5, 2013, the Company changed its name to the current name and moved its jurisdiction to the British Virgin Islands (BVI) under
a certificate of Continuance issued by the Registrar of Corporate Affairs of BVI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company now continues as a BVI incorporated
company with its registered office located at FH Chambers, P.O. Box 4649, Road Town, Tortola, BVI. Its Toronto agent, Portage Services
Ltd., is located at 47 Avenue Road, Suite 200, Toronto, Ontario, M5R 2G3, Canada.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company continues to be a reporting
issuer with the Ontario Securities Commission and the US Securities and Exchange Commission and its shares trade on the OTC Markets
under the trading symbol &ldquo;PTGEF,&rdquo; effective August 23, 2013. Prior to this date, it was trading as Bontan Corporation
Inc. under the trading symbol &ldquo;BNTNF&rdquo;. Effective October 28, 2013, the Company&rsquo;s shares are also listed for trading
in US currency on the Canadian Securities Exchange under the symbol &ldquo;PBT.U&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage develops pharmaceutical and biotech
products through to clinical &ldquo;proof of concept&rdquo; focussing on unmet clinical needs. Following proof of concept, Portage
will look to sell or license the products to large pharmaceutical companies for further development through to commercialization.
Portage seeks products and co-development partners in cancer, infectious disease, neurology and psychiatry with novel targeted
therapies, or reformulations that can be patented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On January 8, 2019, the Company acquired
100% of the equity of SalvaRx Ltd. which has investments in and helped form six immune-oncology companies which are developing
nine products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The current organization chart of the Portage
Group following the completion of the acquisition is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">*</TD><TD>Companies currently inactive.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Summary of our Key portfolio companies including our subsidiaries
is provided below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IOX Therapeutics Ltd.(&ldquo;IOX&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IOX was incorporated in England and Wales
on February 10, 2015 by Oxford University Innovation Limited, Oxford University&rsquo;s technology transfer subsidiary, together
with the Ludwig Institute. As at the date of this Document, SalvaRx holds 15,313 Seed preferred shares having the same rights
as Ordinary shares (an equity stake of 60.49%). IOX&rsquo;s strategy is to develop a new type of immunotherapy against cancer,
originally discovered through a partnership between the Ludwig Institute and Professor Cerundolo, director of the MRC Human Immunology
Unit and head of the Department of Investigative Medicine at the University of Oxford.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On July 1, 2015, IOX obtained an exclusive
licence (with the right to sub-licence) from the Ludwig Institute to use, research, develop and commercialise iNKT cell agonists,
including compounds IMM47 and IMM60, for the treatment of various forms of human disease, including cancer, under the Ludwig Institute&rsquo;s
intellectual property and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SalvaRx has entered into a collaborative
research agreement with Oxford University to support a Phase I Study and Phase II Study that will allow the first human testing
of the lead compound under licence to IOX. This initial trial is aiming to recruit approximately 60 participants in order to evaluate
the safety and efficacy of the lead compound. The costs of these studies will be borne by the Oxford University under the research
agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IOX is currently engaged in meeting its
clinical testing supply requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Saugatuck Therapeutics, Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On August 23, 2017, SalvaRx entered into
a shareholder agreement with Immunova, LLC, a private, Delaware-domiciled biotechnology company focused on use of nanolipogel (NLG)
technology (the &ldquo;Saugatuck Agreement&rdquo;) to incorporate a new company in British Virgin Islands, Saugatuck Therapeutics
Ltd.(Saugatuck). Salvarx acquired 70% of the equity of Saugatuck and Immunova, LLC holds the remaining 30% of the equity of Saugatuck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">NLG technology, invented in the lab of
Dr. Tarek Fahmy at Yale University, allows different combinations of drugs to be encapsulated in a single nanomedicine and delivered
selectively to the tumour microenvironment, thus potentially minimizing systemic side-effects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Saugatuck has acquired an exclusive licence
from Yale University via Immunova for use of the NLG platform for delivering DNA aptamers and certain aptamer-based combination
products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Under the terms of the Saugatuck Agreement,
SalvaRx undertook to invest in an aggregate amount of up to US$1 million, to be released in tranches on the completion of milestones.
The first tranche of US$300,000 was made to Saugatuck to establish proof of concept.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Nekonal Oncology Limited</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 27, 2017 SalvaRx entered into
a shareholders&rsquo;S agreement with Nekonal SARL (&ldquo;Nekonal Agreement&rdquo;), a Luxembourg-based company holding intellectual
property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As part of the agreement, SalvaRx and Nekonal
have formed a new company, Nekonal Oncology Limited, which is working to utilise SalvaRx&rsquo;s management and drug development
expertise to exclusively explore the applications of Nekonal&rsquo;s technology in cancer immunotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Under the terms of the Nekonal Agreement,
SalvaRx invested an initial &euro;600,000, with agreement to fund up to an additional &euro;300,000, subject to certain milestones
being achieved. The initial investment comprised a &euro;300,000 for an option in Nekonal SARL to participate in the funding of
its auto-immune programs and a &euro;300,000 equity investment in Nekonal Oncology Limited giving SalvaRx a 33% equity interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Nekonal Oncology is focusing on the development
of first-in-class antibodies against a novel Tcell based target having potential for use as a monotherapy and combination therapy
for solid and haematological malignancies. SalvaRx is overseeing a work plan to advance multiple therapeutic antibodies towards
the clinic for use in oncology. Ian Walters, the CEO, is the current CEO of Nekonal Oncology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SalvaRx and Nekonal are currently involved
in a dispute regarding the next tranche of funding. SalvaRx claims that Nekonal management committed a breach of duties and fraud
on its minority shareholders. Nekonal management has counterclaimed that SalvaRx is in breach of breach of contract with respect
to the funding arrangement. While litigation is threatened, no legal proceedings have been formally commenced. Nekonal has halted
all development and it intends to so until this matter can be resolved. The Company and Nekonal are currently negotiating a resolution
of this matter. Company management is currently unable to predict the outcome of this matter or make any reliable estimate of a
potential loss exposure, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage Pharmaceuticals Ltd (&ldquo;PPL&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On June 4, 2013, following the acquisition
of Portage Pharma Ltd, the Company&rsquo;s wholly owned subsidiary, Portage Acquisition Inc. and Portage Pharma Ltd amalgamated.
The amalgamated company was named Portage Pharma Limited and was incorporated in the BVI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In July 2014, PPL successfully validated
CellPorter&reg;, a new proprietary cell permeable peptide platform technology derived from human proteins. CellPorter&reg; has
been shown to efficiently deliver an active pharmacological agent or cargo into cells without disrupting the cell membrane. In
a collaboration with the Pirbright Institute (UK), a CellPorter&reg; conjugated CD8 T-cell antigenic epitope derived from mycobacterium
tuberculosis was demonstrated to provoke a specific CD8 T-cell immune response in Balb/c mice suggesting possible application of
this technology for vaccines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PPL has terminated consulting contract
with its CEO, Dr. Marcoux and discontinued further activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PPL is now focusing on licensing or collaborating
its CellPorter&reg; platform with other pharmaceutical companies to develop new drugs (See Portage Glasgow Ltd. below)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage Glasgow Ltd. (PGL)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage Glasgow Limited (&ldquo;PGL&rdquo;),
was incorporated on January 31, 2018 in Scotland, to develop more effectively targeted drugs to treat chronic conditions including
cancer. PPL was allocated 650 ordinary shares in PGL (65% equity) and other two partners with contemporaneous licensing agreement
were allocated the remaining 350 ordinary shares. The CEO of PPL, Dr. Frank Marcoux is the CEO of PGL and the chairman of its Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The University of Glasgow is providing
therapeutic peptides developed through the research of Prof. George Baillie and access to a therapeutic peptide discovery platform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">PGL will focus on the commercialisation
of new therapies aimed at disrupting protein-protein interactions (PPI) in disease pathways which give therapeutic benefit. Candidate
peptides and PPI targets have already been identified from existing research at the University.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PGL management has been working on its development plans and
budget.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stimunity S.A.S.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On February 28, 2018, the Company made
an initial investment of approximately &euro;501,000 ($681,000) by subscribing to 3,780 new Class A shares at a price of &euro;132.50
per share of Stimunity SAS (&ldquo;Stimunity&rdquo;), a Paris based immune-oncology company. The investment gave Portage 27% equity
in Stimunity. In March 2019, Portage made an additional &euro;600,000($688,000) investment in Stimunity increasing its equity to
36%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stimunity is an early-stage research and
development company focused on the development of STING agonists in cancer. The technology, licensed from Institut Curie, Inserm,
and the University of Oxford, is based on a unique biologic approach which encapsulates endogenous STING-activating molecules in
a Virus-Like Particle (VLP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stimunity&rsquo;s first stage of the preclinical
development plan was to unlock the mechanism of action of its main biological drug cGAMP-VLP (STI-001) and to reveal its therapeutic
potential in comparison to competitors that are only focused on chemical approaches. STI-001 by its biologic nature shows a clear
benefit for treating distant tumors in combination with immune checkpoint therapy whereas this effect was not comparable with competitor&rsquo;s
compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stimunity has now started the manufacturing
of its biologic cGAMP-VLP (STI-001) lead compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Intensity Therapeutics Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On April 22, 2016, SalvaRx announced its
investment in US-based Intensity, a private biotechnology company pioneering a new approach to treating solid tumours. SalvaRx
has invested US$2 million in cash for a 9.2% interest in Intensity as part of a Series A funding round.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">On July 11, 2019, the Company entered in
an agreement with Fast Forward Innovations Limited (&ldquo;Fast Forward&rdquo;) to purchase Intensity Holdings Limited (&ldquo;IHL&rdquo;),
the wholly owned subsidiary of Fast Forward that holds Fast Forward&rsquo;s investment in Intensity. Portage has agreed to pay
US $1,298,061 for IHL through the issuance of 12,980,610 common shares of Portage. The sole asset of IHL consists of 288,458 shares
of the private company, Intensity. This transaction will increase Portage&rsquo;s ownership to 1,288,458 shares of Intensity (approximately
9.7% of the outstanding shares of Intensity).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Intensity&rsquo;s platform, DfuseRx SM,
identifies novel formulations that can be comprised of currently approved and effective cytotoxic or other anti-cancer agents for
direct injection into solid tumours. The Intensity products not only directly kill tumour cells, but also improve the presentation
of tumour antigen to the immune system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Intensity&rsquo;s lead product, INT230-6,
shows strong efficacy in preclinical models against the primary injected tumour without the devastating systemic exposure normally
associated with cytotoxic compounds. Moreover, this lead compound can stimulate a potent systemic immune response that affects
distal tumours.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ON June 20, 2019, Intensity announced that
it had entered into a clinical collaboration with Merck to evaluate INT230-6, Intensity&rsquo;s investigational treatment for refractory
solid tumors, in combination with KEYTRUDA&reg; (pembrolizumab). The Phase 1/2 study potentially will be initiated in the second
half of the year and will evaluate the combination in patients with advanced solid malignancies, including pancreatic, bile duct,
squamous cell, and non-MSI high colon cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sentien Biotechnologies, Inc. (Sentien)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage invested $700,000 in Sentien in
August 2015 to acquire 210,210 series A preferred stock, which is fully convertible into equal number of Sentien&rsquo;s common
shares, currently representing approximately 5.06% of Sentien&rsquo;s equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sentien is a privately-owned, clinical-stage
company pioneering new approaches to cell therapy. Sentien&rsquo;s technology harnesses the power of cell therapy with innovative
drug delivery systems to treat a wide range of systemic inflammatory diseases. Sentien&rsquo;s lead product, SBI-101, is designed
to allow for controlled, sustained delivery of mesenchymal stromal cell (MSC) secreted factors. This approach immobilizes the MSCs
in an extracorporeal device, allowing for doses of therapeutic factors that are unattainable by direct injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SBI-101 is the first product application
of Sentien&rsquo;s platform blood-conditioning technology that has the potential to restore balance to the immune system after
acute vital organ injury, such as acute kidney injury.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Sentien raised $15 million up to January
2018 and commenced its Phase 1/2 clinical trial in June 2017 of its lead product SBI-101, a cell-containing dialysis device for
the treatment of Acute Kidney Injury and have so far enrolled seven patients, passing the mid-point of the low dose cohort enrolment.
The data safety monitoring board concluded that there were no safety issues and recommended continuation of enrolment. Clinical
program for acute kidney injury continues. Sentien also developed two other therapies from SBI-101 which are in pre-clinical stages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_003"></A>Summary of Results</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The following table summarizes financial
information for the quarter ended June 30, 2019 and the preceding eight quarters: (All amounts in &lsquo;000 US$ except net loss
per share, which are actual amounts)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid; white-space: nowrap">Quarter ended</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">June 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">March 31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Dec 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Sept 30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">June 30,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">March 31,<BR> 2018</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Dec 31,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">Sept 30,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">June 30,<BR> 2017</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 19%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss (income) - attributable to the owners of the Company</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">1,442</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">1,924</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">283</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">209</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">219</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">(124,766</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">351</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">341</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 6%; text-align: right">333</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,604</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,757</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,015</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,157</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,378</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,489</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">237,128</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">158,919</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">shareholders equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">98,222</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">99,674</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,979</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,229</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,436</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,619</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">171,597</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">237,642</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">159,435</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net profit (loss) per shares - basic</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net profit (loss) per shares - diluted</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.00</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_004"></A>Number of common shares, options</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">As at,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">June 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 30,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Shares issued and outstanding</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,085,789,986</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,098,770,596</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Options granted but not yet exercised (a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,842</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">595,842</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: left">Options are exercisable into equal number of common shares at an average exercise price of US$0.15
and have a weighted average remaining contractual life of approximately 2.47 years as at June 30, 2019.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_005"></A>Business environment</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_006"></A>Risk factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Please refer to the Annual Report in the
form F-20 for the fiscal 2019 for detailed information as the economic and industry factors that are substantially unchanged.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_007"></A>Business plan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Portage is a unique entity in the world
of biotechnology, enabling research and development to produce more clinical programs and maximize potential returns by eliminating
typical overhead costs associated with many biotechnology companies. We nurture the creation of early- to mid-stage, first- and
best-in-class therapies for a variety of cancers, by providing funding, strategic business and clinical counsel, and shared services,
to enable efficient, turnkey execution of commercially informed development plans. Our portfolio encompasses nine subsidiary companies
whose products or technologies have established scientific rationales, including intra-tumoral, nanoparticles, liposomes, aptamers,
cell penetrating peptides, and virus-like particles. In collaboration with our subsidiaries, we create viable product development
strategies, to cost-effectively deliver best-in-class R&amp;D, clinical trial design, and financial and project management, to
ultimately build value and support commercial potential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Development plans for our operating subsidiaries
and associates are detailed under &ldquo;Nature of operations and overview &ldquo;section of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_008"></A>Results of operations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Following details analyze major expenses
for the three months ended June 30, 2019 (&ldquo;2020 quarter&rdquo;) compared to those for the three months ended June 30, 2018
(&ldquo;2019 quarter&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid">Three months ended June. 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;s<BR>
 US$</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">In 000&rsquo;s<BR>
 US$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Income</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Expenses - operating</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">(1,798</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">(164</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.1in; padding-left: 0.1in">Share of losses in associate</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(43</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(69</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Interest earned on convertible loan notes</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(95</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">14</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss for period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">(1,936</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(219</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net income (loss) for period, attributable to Portage
    shareholders</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">(1,442</TD><TD STYLE="font-weight: bold; text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">219</TD><TD STYLE="text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Expenses</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The overall analysis of the operating expenses
is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Three months ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">In 000&rsquo;s US$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">433</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">61</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Consulting fee</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">1,076</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">81</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Professional fees</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">243</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt">Operating expenses</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">46</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,798</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">164</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development costs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">These costs comprised the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">Three months ended June 30,</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid">2018</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center">In 000&rsquo;s US$</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Legal regarding Patents registration</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">51</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">13</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Consultants &ndash; scientists and researchers</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">72</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">48</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Other outside services &ndash; lab testing, peptide handling etc.</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">310</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">433</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">61</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Significant increase in costs during the
three months ended June 30, 2019 was mainly due to Salvarx group companies which were acquired in January 2019. Number of consultants
increased from one in the 2019 quarter to four in 2020 quarter. Outside services costs included approximately $206,000 on clinical
testing supplies manufacturing by third party suppliers and approximately $100,000 incurred by PGL in peptide synthesis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended June 30, 2018 no new research
work was conducted at PPL or EyGen. Management of these subsidiaries was mainly involved in analyzing the results to date and working
on new patents registration. Significant decline in consulting costs was due to resignation of Dr. Littman as CEO of PPL and EyGen
and Dr. Marcoux taking over that role in addition to his role as CSO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further details regarding development activities are provided
under &ldquo;nature of operations and overview &ldquo;section of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following were key activities during the three months ended
June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IOX</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">IOX successfully manufactured its active pharmaceutical ingredient
at a new manufacturing facility. This material will be placed in a liposome for delivery to humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Stimunity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Stimunity continues to study its lead drug
in animal models of cancer. The company has studied its mechanism of action and shown that it has superior efficacy to competitor
products. It continues to scale its manufacturing process and do the testing to enable a clinical trial application in the coming
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Saugatuck</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Saugatuck was able to successfully package
a DNA aptamer in the nanolipogel formulation licensed from Yale. The aptamer was fully functional upon release from the particle.
The team begun to characterize the properties of the aptamer in and out of the particle and compared it to the similar targeted
antibody. The company is pleased to show that the aptamer-based formulation was superior to the antibody in control the dissemination
of the cancer (reducing metastasis). The company will begin to explore combining the aptamer with other aptamers and small molecules
to look for synergy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Intensity</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">progress continues on recruitment in its
clinical trial. Results were presented at ASCO meeting in Chicago showing the safety in human subjects. Also, in June Intensity
announced a clinical collaboration with Merck to study its drug in combination with pembrolizumab.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Consulting fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Consulting fees include cash fee of $321,000
and value of vested options in IOX of $755,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Approximately $239,000 of cash fee and
all of the option value related to Salvarx operations which were not part of Portage in 2019 quarter which explains significant
increase in the consulting costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has no employees. Most of the
consulting fees relate to fees charged by four key consultants including CEO and CFO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Consulting fees include cash fee and vested
options for the three months ended June 30, 2018. During this period, no new options or shares were granted. Cash fee included
fee charged by the CFO of $45,000 and $21,165 charged by an independent valuer retained in connection with the proposed acquisition
of SalvarX Limited, representing 50% of their charges, being Portage&rsquo;s share of the cost.</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Professional fees</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Three months ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Professional fee was made up of $53,000
towards legal fee and $190,000 towards additional audit, accounting and other non-audit services fees for fiscal 2019 and accrual
of $25,000 towards the fiscal 2020 audit cost.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Approximately $33,000 of legal costs related
to the time spent on regulatory extensions and fund raising efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Professional fee for the three months ended
June 30, 2018 included accrual for fiscal 2018 audit fee of $10,000 and balance $3,000 includes legal fee relating to general
corporate matters and review of certain licensing agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Other operating costs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other operating costs include Toronto office
costs, transfer agent costs, press releases, directors and officer&rsquo;s liability insurance premium, web site related costs
and bank charges.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Costs increase during the three months
ended June 30, 2019 was mainly due to additional costs related to Salvarx operations which were not part of Portage during the
three months ended June 30, 2018.Aproximately $15,000 was charged by a investor relation firm hired to re-do the web site and prepare
presentation materials</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Three months ended June 30, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Costs for the three months ended June 30,
2018 included rent for the Toronto office of $3,198 and regulatory filing fees of $ 3,008. Significant decline from the previous
period cost was due to absence of any press release costs and shareholders meeting costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_009"></A>Liquidity and Capital Resources</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Working Capital</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at June 30, 2019, the Company had a
net working capital of approximately $3.6 million and cash on hand, including short term deposits was approximately $5.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">As at June 30, 2018, the Company had a
net working capital of approximately $9.7 million and cash on hand was approximately $7.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating cash flow</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended June 30, 2019, operating activities
required a net cash outflow of approximately $1 million compared to $185,000 for the prior period. Significant increase in cash
requirement during the three months ended June 30, 2019 was mainly due to operating costs of Salvarx group companies which were
acquired in January 2019. Cash requirement was met form the existing cash on hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three months ended June 30, 2018, operating activities
required a net cash outflow of approximately $185,000. The cash outflow primarily included consulting fees and research and development
costs which were met from the existing cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company is required to support further
research and development at its subsidiaries, mainly IOX and Saugatuck. It also has commitments to providing more equity funds
to its associates once they achieve the agreed milestones. &ndash;No further activities will be carried out at PPL, PGL and EyGen
until they could find a financing partner. the Company plans to seek additional financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company has not yet determined whether
costs incurred and to be incurred are economically recoverable. The Company&rsquo;s continuing operations are dependent upon any
one of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">The existence of economically recoverable medical solutions;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: left">The ability of the Company to obtain the necessary financing
to continue and complete the research work on various products in its portfolio;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Securing partnership with other Pharma companies</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">future profitable production from or proceeds from the
disposition of intellectual property.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Although there are no assurances that management&rsquo;s
plan will be realized, management believes the Company will be able to secure the necessary financing to continue operations and
successfully monetize SalvaRx portfolio, into the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">I</FONT>nvesting cash
flows</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There were no investing activities during the three months ended
June 30, 2019 and three months ended June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Financing cash flows</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There were no financing activities during
the three months ended June 30, 2019 and three months ended June 30, 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_010"></A>Key Contractual obligations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Details of contractual obligations, commitments
and contingent liabilities are provided in note 14 to the unaudited consolidated financials for the three months ended June 30,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_011"></A>Off balance sheet arrangements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">At June 30, 2019 and 2018 the Company did
not have any off-balance sheet arrangements, including any relationships with unconsolidated entities or financial partnership
to enhance perceived liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_012"></A>Transactions with related parties</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Significant related party transactions
are detailed in Note 16 to the unaudited consolidated financials for the three months ended June 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_013"></A>Financial and derivative Instruments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s financial instruments
recognized in the balance sheet consist of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fair value estimates are made at a specific
point in time, based on relevant market information and information about financial instruments. These estimates are subject to
and involve uncertainties and matters of significant judgment, therefore cannot be determined with precision. Changes in assumptions
could significantly affect the estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0">The following table summarizes the Company&rsquo;s
financial instruments as at June 30, 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As at June 30, <BR>
2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As at March 31,<BR>
 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value to other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value to other comprehensive income</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">in 000&rsquo;$</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><U>Financial assets</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Cash and cash equivalent</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">5,187</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">6,166</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Prepaid expenses and other receivable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">429</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">282</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>Investments</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">88</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">103</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="font-weight: bold; background-color: White">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left; background-color: White">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right; background-color: White">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; background-color: White">&nbsp;</TD><TD STYLE="text-align: right; background-color: White">&nbsp;</TD><TD STYLE="text-align: left; background-color: White">&nbsp;</TD></TR>

<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FYTPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amortized cost</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">FYTPL</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><U>Financial liabilities</U></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Accounts payable and accrued liabilities</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">1,411</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-weight: bold">&nbsp;</TD>
    <TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-weight: bold; text-align: right">-</TD><TD STYLE="width: 1%; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,107</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Unsecured notes payable</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">3,665</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">-</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,663</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Warrant liability</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; text-align: right">2,475</TD><TD STYLE="font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,475</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">A summary of the Company&rsquo;s risk exposures
as it relates to financial instruments are reflected below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fair value of financial instruments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s financial assets and
liabilities are comprised of cash, receivables and investments in equities and private entities, accounts payable, warrant liability
and unsecured notes payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company classifies the fair value of
these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Level 1 &ndash; Values are based on unadjusted quoted prices available in active markets for identical
assets or liabilities as of the reporting date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Level 2 &ndash; Values are based on inputs, including quoted forward prices for commodities, time
value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either
directly or indirectly observable as of the reporting date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">&#9679;</TD><TD STYLE="text-align: left">Level 3 &ndash; Values are based on prices or valuation techniques that are not based on observable
market data. Investment is classified as level 3 financial instrument.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Assessment of the significance of a particular
input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Management has assessed that the fair values
of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term
maturities of these instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The following methods and assumptions were
used to estimate their fair values:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Investment in Biohaven: Fair value was
based on quoted market price of $43.79 per share (Level 1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The investment in Nekonal and the option in Nekonal has been listed
at a $0 fair value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Investment in Sentien: fair value of the
asset is determined by considering other comparable equity funding transactions by Sentien with unrelated investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Investment in Intensity: fair value of
the asset is determined by considering other comparable equity funding transactions by Intensity with unrelated investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Unsecured notes payable and warrant liability:
The fair value is estimated using a Black Scholes model (Level 3).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">There have been no transfers between levels
of the fair value hierarchy for the three months ended June 30, 2019 and year ended March 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s financial instruments
are exposed to certain financial risks: credit risk and liquidity risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Credit risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Credit risk is the risk of loss associated
with a counter-party&rsquo;s inability to fulfill its payment obligations. The credit risk is attributable to various financial
instruments, as noted below. The credit risk is limited to the carrying value as reflected on the statement of financial position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cash&ndash; Cash is held with major international
financial institutions and therefore the risk of loss is minimal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other receivable &ndash; The Company is
exposed to credit risk attributable to its debtor since a significant portion of this amount represents the amount agreed on a
settlement of a claim by PPL (Note 4), payable over the next six years. The debtor has so far been diligent in paying the amounts
on the due dates and PPL management will be monitoring the account on a regular basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Liquidity risk</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Liquidity risk is the risk that the Company
will encounter difficulty in satisfying financial obligations as they become due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company&rsquo;s approach to managing
liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both
normal and stressed conditions without incurring unacceptable losses or risking harm to the Company&rsquo;s reputation. The Company
holds sufficient cash to satisfy obligations under accounts payable and accruals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Company monitors its liquidity position
regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects. The
Company believes that it has sufficient funding to finance the committed drug development work, apart from meeting its operational
needs for the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">However, as a biotech company at an early
stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the
possibility that additional financing may not be available to the Company, or that actual drug development expenditures may exceed
those planned. The current uncertainty in global markets could have an impact on the Company&rsquo;s future ability to access capital
on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_014"></A>Use of Estimates and Judgments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The preparation of financial statements
in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting
policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Estimates and underlying assumptions are
reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the year in which the estimates are revised and
in any future years affected. Significant areas where estimation uncertainty and critical judgments are applied include valuation
of financial instruments, valuation of property, plant and equipment, impairment losses, depletion and depreciation, and measurement
of stock based compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_015"></A>New accounting standards, interpretations and amendments</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">During the current interim period the company
adopted the requirements of IFRS 16 in respect to lease obligations. However, management determined that it had no leases to which
the standard applied, and therefore there was no impact on its financial statements. The Company is also unaware of any applicable
but not-yet-adopted standards that are expected to materially affect the financial statements of future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_016"></A>Internal Controls Over Financial Reporting</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our Chief Executive Officer and our Chief
Financial Officer (&ldquo;the Management&rdquo;) are primarily responsible in establishing and maintaining controls and procedures
concerning disclosure of material information and their timely reporting in consultation and under direct supervision of the audit
committee which comprises three independent directors. We have also instituted controls involving dual signatures and approval
processes. We plan to introduce more rigorous controls as our activities expand. However, given the size and nature of our current
operations and the involvement of independent directors, significantly reduces the risk factors associated with the inadequate
segregation of duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Management has instituted a system
of disclosure controls for the Company to ensure proper and complete disclosure of material information. The limited number of
consultants and direct involvement of the Management facilitates access to real time information about developments in the business
for drafting disclosure documents. All documents are circulated to the board of directors and audit committee according to the
disclosure time-lines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><A NAME="portage_99-2_017"></A>Public securities filings</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additional information, including the Company&rsquo;s
annual information form in the Form 20-F annual report is filed with the Canadian Securities Administrators at www.sedar.com and
with the United States Securities and Exchange Commission and can be viewed at www.edgar.com.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">15</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #C KP# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^"?VIM'UCX@?M$_LE_!]OB+\5_ 7@KQGI?[0WB+Q5!\)?B/XG^%
MVLZ_J/@?PUX%/AB/4O$G@Z^TO7IM-TR7Q%JMT-*CU"*QNKN2WGO8;DVD"I][
M5\4?&;_D]G]B3_L3OVLO_4:^%- "_P###7@K_HOG[:W_ (F1^T!_\VU'_##7
M@K_HOG[:W_B9'[0'_P VU?:U% 'Q3_PPUX*_Z+Y^VM_XF1^T!_\ -M1_PPUX
M*_Z+Y^VM_P")D?M ?_-M7YC_ +=?_!3O]I']GW]K#XX_!SP!\:/^"9'P7\!?
M!'X(?"GXLVND_MK^)OB9X1^*?QGU#QK!\0[_ %_PU\)KCPG\1-)T_6KC3H?!
M-CI4-O8^"];U73]5\2:4SV&N"ZCLU^N=2_X*T?!3P%\-/V>O$'Q:^&/Q^TOX
MM_&3]G?P+^TQX]^!7PE^"_Q*^.GC7]GGX5^*=-MY-<^('QCC\#^%6N?"/P\\
M*Z[_ &IH<WB'7-,TO6-4FT?46L?"[7-AJ=E8?O6,^C3XOT,@X'XAP'#M'B+"
M^(&!HYCD6"X;QM3,,VI8;$<.4^+*53-,)C\IX7P>%I_V#6H8JOB\#Q%Q%E>!
MQ6*P.2YGF^6<0YEE7#V;>;+-L##%8G!U*DJ=7"N<:LIQ7LW.F\!&5.FX5*M:
M=1RS/!0I0^IPEBJE65/!+&U*->%'W_\ X8:\%?\ 1?/VUO\ Q,C]H#_YMJ/^
M&&O!7_1?/VUO_$R/V@/_ )MJ\F\=_P#!57]G3PWXWL/ASX \&_M"_M#^+-=^
M 7@[]IKPPG[.WP/\:?%G0==^#7C_ $3QEK7A/QD?$?ANUGTW1=.U8>#UTRR3
MQ ^EWNJZQXG\,:9X>L]:O;O4(=,\$^$7_!:'X<:[^Q=\%/VI_BW^S]^U!H?B
M;XM:9XPUJ3X3_"[]GGXG_$;7++PMX"M-(U;QI\4M+FL]+CM;KX&^&]+\2:#C
MXLZS>:#I'B*:6]FT6P8V&IV>F>9A?H\>->-RK!9Q0\.L^^K9EFV3Y+EV&KSR
M;!9MCL=GV"XCS#+'0R7,.)<NS>&#K8;A+B'VF88[ 93@L-6RVMA\16IUG!3J
M6:Y?&I"G]:I3E.-:2=+GJPBJ&%R_&S4JE*G4@IRPV:Y=5HTTZE6NL70C2I2J
M5:5*K]J?\,->"O\ HOG[:W_B9'[0'_S;4?\ ##7@K_HOG[:W_B9'[0'_ ,VU
M>9_$7_@JU^R'\/D^%]Q;ZI\5OB78_%/X$2?M06>H_![X)_$SXDVO@;]GAM/O
M;S3?C%\5E\/>'9KKX;>!M:O;"YT&QU;Q1;67V;68ITUJ+2=/LM0U&TY#X@_\
M%COV+OAIH'P,\3>(]0^+MUI'QP^"G@7]I![GPK\&_&WC6/X,_ 3XC0/)X6^+
M/Q\F\)V&L6WPU\(7EQ;ZA8R7-S<:C>I<Z1JTJ6,MA837HX<%X#^-.8K+/J/A
M9QQB99Q5S*AEE.GD555L97RBEF-;,J,,/5QM#$TJN%IY1F+=+&X;+JF(EAG2
MR^&:5L1@:&8MYKEJ@ZCQ^%]FJ$,3SJM&470JT\/5IU(N$9\ZJ4\5AIPC3]K4
ME&O2M1O-1/>_^&&O!7_1?/VUO_$R/V@/_FVH_P"&&O!7_1?/VUO_ !,C]H#_
M .;:N1_X*-_M8>,OV6/V.-;_ &A?@SJGP:;7I?&7P(\->'?%?QKFUN;X*:-H
MGQB^+G@/X?7?COQK?>%/$'AO58_"'AS0?%]QXIO=4L-;MH[:PL&OI/M%M&\,
MOYZ_!W_@J;^T'J7A?]N6'QUX\_8$^.__  S%^R#KG[3FA_M,?L3ZO\2OB;^S
M?X3\06=OXUBTSX1_&#0Y_&^N^(M7\83Q^#[SQP-.\"_$"QO;WP;:7UE)!HVJ
M2Z??7'K<(?1[\2...":O'N08;)9Y+1XBJ<,2PV-S3%X'-Y9E0SS@CAS%..$G
MPKB<OA3PV;^(?"^&>'Q/%&7YYC7BL8\EX8X@GEF/HT<\3F^"PN(PF&J3G*>.
MI4:]"=&$:M%TL14QE*A-U(UXMQJSP-?EE2I8F,(.E7K2H8:K'$K]./\ AAKP
M5_T7S]M;_P 3(_: _P#FVH_X8:\%?]%\_;6_\3(_: _^;:O#?'/_  5H_9@^
M#DOA+P]\2+OXG>*/$%I\*OAC\4OCYXN^"_P(^*OQ"^%G[-GA?XG>&8O$'AKQ
MA\>/$GA[2?$$/PC\->);:/4-6T33_$%_J7B.R\.P1ZSK-G#I,UKJUYQD/_!7
M#X;:!^U9^V=\&?BM\/O'WPU^!G[(GP<^&GQ6O?VDK_P5XLU/X?>)K7QG%J$]
MPYUS3].ET^&#Q5+/H&D_ K3-!3Q)JWQIU"T\9GPQNFT!=.GY,']'SQGQ^&QF
M,POAYQ#4PN%R:OG]*K/#X>A+-<LH\1Y)PI&>187$8^AF&<XS%YSQ)D4,NRC!
MY9#.\RR_-,'G.7Y+C<EQ%#-L15+-<OKTJ56GB:;56&55%3;_ 'L8YS"E4P$J
MD(\ZA&4*U-UZGM94L)S1^MUL-STO;?4O_##7@K_HOG[:W_B9'[0'_P VU'_#
M#7@K_HOG[:W_ (F1^T!_\VU>+>&/^"O/['GB3X->/_B]/<?&3PIJ?PW\;> O
MAIK_ ,"/&7P2^(.@_M*7OQ'^+LLD/P8\#>%_@K)I,_BGQ;K_ ,8FBD;X=KX>
MCU'3]8CMM2EN[_3H]"U]M+\T^*G_  5@\.:+I/['GC[X>>!?B';>"_C1^TYX
MS_9^^-_P]^)/P"^,ME^TC\/=6\*? _XB_$E?!6A?!;1[.+QHWQ2U#Q'X<\):
M9IVGP^'/&>EZSI>OG^RXY3=0ZM8/!?1\\9\7F,\KJ>'O$.6XF&8YCD\IYQAZ
M&687^ULLX;S'BRME]/%5LPK4L15Q&3994G@,7@UCLEQN+Q>68"EQ+2Q>8X:D
MG+-<OC0>(6*I5*?L*^(BJ;<JDZ6&K4:%=PA*--WIU*\4X3=&<HTZ\J<:L:%1
MKZT_X8:\%?\ 1?/VUO\ Q,C]H#_YMJ/^&&O!7_1?/VUO_$R/V@/_ )MJ]3_9
MA_:9^&7[6_PDTWXQ_"H>++/0KK7?%/A'6_#?C_PEK/@/Q_X(\<>!M>OO"_C3
MP-XY\&Z_!;ZIX=\5>%O$&FWFF:MI\ZRQK+$)K2YNK2:"XD_+G]GW_@LYX3U'
M]EO]D/XD_M$_#CXE:]\>_P!JGX7?&WXD^&_AG^R9\"OB;\6X];C^"/CIO#/B
M#2?#WA;1+_QMXKTN[DT>\T[65N_$6H'PU;16>MW&K^*-&1=.MKOS<H\%/%#/
M:G$F$RKA',<5F_"7$F#X4S_AY2PM'/\  9QB\GXAS^4:F7XK'82C]2P&4<+Y
MMCLTS.6<T<OP&&CA,3/%XC!XW#XYZ?VA@W3H557C*CB8UY4JR4O9VP\J%.JI
MN4(SIS5?$T<*J4Z*K/%R>&]A&O&5-?>?_##7@K_HOG[:W_B9'[0'_P VU'_#
M#7@K_HOG[:W_ (F1^T!_\VU>/>+_ /@K=^R)X=\ ? KXA>%W^-'QIM?V@_AK
M=?&GP=X5^ GP-^(WQ=\?>'_@QHVH:=HWBOXL?$?P?X2T:]U;P#X&\&Z]J<'A
M_7]3\01VUP^NV^I:5H=EK5WI&IQVGZ*^$/%GA[Q[X4\,^./".IQ:UX5\8^']
M'\4^&M7ABN8(M4T'7]/M]5TC4(X+R&VO(%O+"ZM[@07=O;W4/F>5<00S*\:_
M.\2>'O'7!V"P68\5\(Y_PY@LQQ^:Y7@L1G.7SP"Q&8Y'B\9@,VP2HUJ[Q=&O
M@L7EV8T)1Q> P,,1++\?/+ZV:T,#C,5A:H8[!XF4(8?%4*\IX:CC(*E-3Y\+
MB(J5&O%J/+*G4C*$E:3DHSIRG3IQJ4Y5/DO_ (8:\%?]%\_;6_\ $R/V@/\
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M/0E2IN,)TZ-6K.I33Y7&2I^\XTX4SXX^)/\ P23^(&O2?%W1OA/^V1JGP?\
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M]%_\)_\ \%*_^C2_V&O_ !8;\?/_ *6#1_PG_P#P4K_Z-+_8:_\ %AOQ\_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>>^+?BW\*? .HP:
M1XZ^)WP]\%ZM<V4>I6VE^+?&GAOPYJ-QITL]Q:Q7\%EK&I6=S+92W-G=V\=U
M'$T#SVMQ"LAD@E5>7_X:3_9T_P"B^_!7_P .GX&_^7M 'M5%>*_\-)_LZ?\
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M>T >U45XK_PTG^SI_P!%]^"O_AT_ W_R]H_X:3_9T_Z+[\%?_#I^!O\ Y>T
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MT7WX*_\ AT_ W_R]H ]JHKQ7_AI/]G3_ *+[\%?_  Z?@;_Y>T?\-)_LZ?\
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MM(D+(KL S GFOJC_ (9H_9Q_Z-_^"7_AJ? G_P H:\0\!?\ *2#]JW_LR/\
MX)^?^KW_ ."F-?;E 'B7_#-'[./_ $;_ /!+_P -3X$_^4-'_#-'[./_ $;_
M /!+_P -3X$_^4->VT4 >)?\,T?LX_\ 1O\ \$O_  U/@3_Y0T?\,T?LX_\
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M^SC_ -&__!+_ ,-3X$_^4-'_  S1^SC_ -&__!+_ ,-3X$_^4->VT4 >)?\
M#-'[./\ T;_\$O\ PU/@3_Y0T?\ #-'[./\ T;_\$O\ PU/@3_Y0U[;10!XE
M_P ,T?LX_P#1O_P2_P##4^!/_E#1_P ,T?LX_P#1O_P2_P##4^!/_E#7MM%
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M_#-'[./_ $;_ /!+_P -3X$_^4-'_#-'[./_ $;_ /!+_P -3X$_^4->VT4
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MKN^/W_TT*C_A7_\ P4O_ .CMOV%__%=WQ^_^FA5]T44 ?"__  K_ /X*7_\
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M#OP\UJWTSQ-<ZUJEUKVN:YK\.L6_AS5M&T;1?HO_ (5__P %+_\ H[;]A?\
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MV.8Y;@<SH<[C&"C4C2QJI5Z;3=.M1G'FE&46OA?_ (5__P %+_\ H[;]A?\
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MG6OQT\9D7T?CK4-"O+2]N+?5O">I:A'H6L>'OT8K\Y_CC_RDC_9"_P"S&?\
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M^_\ TT*OJJBC^R,O_P"?#_\ !E3_ .2#_B(?%O\ T,X_^$>$_P#E9\J_8_\
M@I;_ -'5?L,_^*\?C[_]-"H^Q_\ !2W_ *.J_89_\5X_'W_Z:%7U511_9&7_
M //A_P#@RI_\D'_$0^+?^AG'_P (\)_\K/*/V'OB-\9?B-\._B>WQX\8^#_'
M?C_P+^T5\:/AG-XD\ _#RZ^%?A"ZT3P9XE%AH4.B>!M2\<?$W6=&MK33WC@D
M_MOXA^,-5O+E)KVXU@I/%96?V?7PI^P9_P BS^TK_P!GI_M*_P#J7P5]UU\;
M6BHUJL8JT8U:D8KLHSDDM==$D?T=EM:IB,NR_$59<U6O@<)6JRLES5*N&HU)
MRLDDKSG)V225[+0^*/V&?^1)^/G_ &>O^V5_ZT#XWK6\>_M8ZGX<^/\ XA_9
MS\ ?L[?%_P"-/C3PA\)_AY\8O%6I^"M?^!GAOPWH_AGXG>+?B7X.\+V8N/BI
M\7_A_JVHZS)J7PH\4SW\.F:/=V%C9G3&DU$W%\+>/)_89_Y$GX^?]GK_ +97
M_K0/C>O.?%/['U]\3_V]/BI\:O'3_%;0OA;J7[*_[.WPY\':[\*?VD_C+\#K
MG5_'G@CXK?M+^)O&6E>(](^!OQ2^'^M:_:Z1H7C_ ,%76E7?C*TU+2(7UC5+
M;P]+'</X@C;] \.,)P7B,=Q+6XXJ4H9?EO!>=9EE-*K4S1+%\1T<QX4PV686
M&$R7-LCS/,ZE3#9CGE6.787-L&ZBPL\75G5H9=5P]=XZ6)CAT\(FZ\L7@:6D
M82:H5<3*&)E^\A4A!0HI2=64)QI?&X24K+<\#?\ !3/]DWQCK?AO2=7\?Z9\
M*K+Q5\.]%\;Z1XA^,OB/P+\-=$G\0ZG\7_B)\"M1^$,<OB'Q?;W=[\5_#'Q,
M^%_BGPYK6@Z5::CI,]S%9_V!KVMB[CKZM\7_ !U^"/P^\8>#OA[X]^,?PK\$
M>/\ XB2^1\/_  /XO^(7A'PUXP\=3F58!#X.\,ZSJ]EK7B:7SV6'R]$LKY_-
M98]N\@5\+ZU^QS=>&OBW\9!\+?AAX;TGX27_ /P3CM?V9/AE:Q7NB$#QC+X^
M^,_B'6O",D6KWL^MI::S;^*?"NJZ_K^MN]AXBU.X-YK.I:AJEG=2Q?#?Q8_9
M"_;;\0?!;XF?"BP^''B'6O%/CW]EK]EGPMX+U?PC\1O@;X ^&>G>/_@MX#\#
MV7C&S_:'\7"\LOV@_B!\3[3QQIWBR7X=Q:3+XZ_9_P!5\)Q^'=$UB7P)>ZEX
MTUW7?V;!^&G@;Q=F^5SR;CS$<%9+B\-E#QN%XCXCX3Q>/P?]MTJU>./E6QJP
M,*?^K,,5@_\ 6S+:]>=5PP&)CDU7ZU*IA\1Y^)QF98.EBYO#+%RI4:DZ"I4J
M\W.K1PE*M&E+V$+5%B:DOJT:E*E%PQ<IM4WAU3A0_:?5_P!JC]F'P_X@UOPG
MKW[1WP&T3Q5X:O(-.\1^&=7^+_P^TWQ!H&H7.O:%X5MK'6]&O?$,.HZ5>7'B
M?Q3X9\.06M_;03RZ]XCT+1XT;4-7T^WN'>$?VI?V9/'^I>!]%\!_M&? CQMK
M'Q.M?$-[\-=)\(_%WX?^)-2^(5EX1D>+Q9=^![#1O$-[=>++7PQ+%)'XAN-
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M-'QT^'/P9\+>)?"<,/A2S\,>&OC!IWAGQ)K]]%KOBSP?X#GT2?7O$?HOA?\
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M.=Y]K5^<_P <?^4D?[(7_9C/_!13_P!: _X);5^C%?G/\<?^4D?[(7_9C/\
MP44_]: _X);5VY=_OV%_Z_1_*1\UQC_R2V>_]BZM_P"E43Z@J.::*WBEGGD2
M&""-YIII&"1Q11*7DDD<X"HB*6=B<*H)/ J2JE_'?2V-[%IEU!8:E):7,>GW
MUU:/J%M9WSPNMI=W-A'=V$E]!;W!CFFLTOK)[F-&A6[MF<3)][!*4X1E)1C*
M<8RE)M1C&4HJ4I-0J-1C%N4FJ=1I1;4)M*$_Y7IJ,JE.,VHPE4@IR;Y5&#G!
M2;ERSY4HN3<N2?*DY<D^7DE\J?"C]K.S^+T'PS\4^'?@G\:XOA!\:8=.O?A1
M\:AH_A'Q#X+\3Z/K?AS4O%?A_P 2:WH_@SQEXE^('PV\+:_HVFE].\1_$WP=
MX2TF'4=2T+1-7N=*UG6].L)O0;_]I?X%QI\8+/PY\5/AYX_\8? CPMKGBSXH
M?#7P#X^\%>)OB/X0LM#TO4-4DM/$7A"R\0?VIX;U"^CTVYM=.B\2QZ-!/>+Y
M4EQ"BRR1_GW\,/V6_B1X8^*/PK\1?#_X"7?[*?Q+\,^,-,\1?M(_$OX8_%73
M;;]CGX]:%<:)KD7Q!\/_  ^_9QT7XJ:[J^IWGCKQ/>:;J^CZA\3/@?\ ";Q+
M\-&EOM=TGXD^(M4TB32/'?C?AS]E7]KC4[;X$Z;KWPX\3:3>_"/X$_M<?"'Q
M]<:O\1?@;HWPJO?$GQ6^#UCX?\'VO[,GPL^$=]8:/I7P'U#QEI<-CH&N?%GP
MWX)^.NAZ-8^&%\:Z-?7&I^.O$D_]/8GPV\(\PS3%XC"\9Y;D&4X7#*OA\LJ\
M3Y/CL=*-+-,?5H?VKCJN;9C@\=1SC)\NIY?@<SX2Q>'KU\9FV!SK,."^"IRE
MPY1]*GAL-*LG4;5/GP3E#VM.G&G3K8FBJL*CYJLU5^JSJ2_<U<51ISHNH\6H
MU'1H_L+X7^-WPP\3^!(_B&/&?AC0]"MK'P9<>)QX@\3^&K"X\!:GX]\->$_%
MOAKPQX[D35Y[#PSXFU#0_'7@^^M=(U"]2:^MO$N@W>G&\LM:TJYO+VF?&?X.
M:W\2-7^#>C_%SX7ZK\7O#]HFH:_\*M.^('A.^^)6A:?(D<B:AK/@2UU>;Q5I
M=BT4T4HN[W28+<QRQN)"KJ3^?-O^R?\ &.+XJ?LZ6D&DZ!;?!/7O _P#\1_M
M6VT_B*W.J67Q6_9*\.!?AAI>D:1$;NV\2KX\\2ZAX'CUS5=.>/3].T/X#00W
MUU.?$&BQOP'@3]GG]J<?&;]F74O%W@KQ):V7P0_;*^-/Q=\<>)K7QY\'/#?P
M#/PX^)OPN_:,\+Z,_P !_A'\.[JR\7Z[/<7WQ'\,S>/]<^/7AG3OBOIWBW6/
M%5_H>N>/]*UO4]>TWYO_ (AOX;8FGG&)PWB1@Z,89'G.=97A)8_(?:X6M1?%
MU'*<IS!8JI0KXS$5<QX2E@ZU++ZD\PGEO%G F;TL/5GFV-C2Y<+AX5,)"K6G
M:LL#@\14BYTX-UJV#PN)J4G22YHS56..PM2G&3EA\4Z%.473A)U??_ ?_!0K
M3/&'PL^'7Q]UG]F_XY_#[X _$O5O NDZ3\6?%.M_ "_TW2#\2_'FD_#/P3J/
MB+PGX-^-GBCQ[8Z;J_C37]#TJYFM?#&H7&BQ:G'J.L6UG86M_<6GVK8?%/X8
M:K+X>@TOXD^ -3G\7:_XL\*>$X=.\9^&[Z7Q3XI\ SZM:^._#7AR.UU.5M<\
M0>"KG0-=MO%VBZ6+K4O#4^B:O#K5M92:;>K!^.WPC_X)_?%3X3?LQ?L@ZB=(
M\>>._BO\#]9\#Z_\8/V5O'_[1_CWQQ\%/B##IGC.WU62X\&>&?%OQ1U+X)^"
M/B7\(;N'3?BA\&;O1K71O '_  E?AV/P_K-II[:KIOBKPC[U\#?V<OC-X(_;
M/\>?M0^(?AGX:LO!WQVU;XF>'#X!C\46=[KW[-]CIUQHIT7XOZ1$/%>I>";K
MQ!^UC%X0L=2_:.TKX>VSZW::SH_P2CENO$B^'/'NL#W^-^!O!>K4XNQ7!_%N
M#P6&R"IQ['(\/0SBG6CQ)B,DXIK9=PSD,:'%6;9AFTL9C>&Z57B:/&&7UH<)
M\29?0CE^4X+*^)LPR[+I:XFCAD\14H-\E.=:-*GSP_>\N99G0O!7G5@L/@:.
M!Q$XUY3GBXU8U,)-^UG"G^I5%%%?S(>>>&?L&?\ (L_M*_\ 9Z?[2O\ ZE\%
M?==?"G[!G_(L_M*_]GI_M*_^I?!7W77Y[B/X]?\ Z_5?_3DS^OLG_P"11E7_
M &+,!_ZAX<^*/V&?^1)^/G_9Z_[97_K0/C>OM>OBC]AG_D2?CY_V>O\ ME?^
MM ^-Z^UZQ/2"BBB@#YL_9D^/=]^T#H7Q:UB_\+VGA5_AI^T9\<_@5;V]IK$V
MLKK%E\'_ !UJ'@^U\332S:9I9L;K7XK(7]QI,<=W%ILDAMH]1OE43MX9I_\
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MMW\1KS5/@_XM^,O@K2/ /@WXD^/[;5/"7AK2-2NX_$GC#4OAQX)\9?\ "L?
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MV8/@/\#OV=OVZ_VMO G[/WP9^%'P+\$:C^R?^PGXMU#P;\'/AUX0^&/A6_\
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MAP8N.+E.I'#RE&/L,N=)Q<(MU%FCEF$9RE&22>"C24-IRI^VA3<>>3>#\/\
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M@F1)894>.1%=2!ZC0!\4^ O^4BO[57_9E_[ W_J[O^"D-?:U?F;XH^.'P_\
M@#_P4"^/VM_%/_A.=%T/QS^Q[^Q7I?A37-%^$GQ:\=:'K.J>#OC1^W_=>*=*
MM]:\ ^"/$^E1ZKH%KXO\+7>JZ7<WD.H65GXBT2[GMDMM4L99_7/^'A?[*O\
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MIT5)0P3K5*-*.(PSQ-6&)P\L7A)5*&(AJ^)/VY/B;XD\7>.V\':WX1\":#\
MT^"Y^(5Y<^&=1^(_P4U*]^)WP@\,_&#6;SXG_'?0$:V^'/PQATSQAI'A[POX
M]\":3XRO-$>VN?B=XVT:[^'FK:+;/K6_[;GQ7T;]I_XP?#K7K3PQJ.@^&[SX
MGZ%8_#"2QC\.>(_AM:^%K/X7K\"?B3XS\;W6IW$+>#?VE]0\7^.;W3-6U32-
M/T33O#O@;7;_ $"ZNA\*/BQ*/!'_ .&'M"\,:S\)OAI\7_BSX&_9^^(_PY^'
M'PH^-GPIN/V4_P!HSQ+=>-_!?PK^&ND?!_P[#X5\;W'PVT[5/ 6M>(?ACX>\
M.^ _B%J\]AXO.M^'?#FC3^%;3P+XL75/%6J_3_Q9_:7_ &+_ (UVFI>'_'GC
MOXNW?@?4_AS\0/A[-X1TW]G?]I33;?/Q+\/7G@SQ'XG;48_A%)=G7K/P7J.K
M^&_#4D8AM]'M_$?B2ZEBU&[OM/DTC]%QO%O@5AZU'"8+A?"YAD>,RG$98L14
MRFOA\^R?#QJ9!7>:8N#:=?B/&YI0S^M0R_!YWC<-@<E>6X>CQ?2I8W-,I/-P
M>&S-PHK&XJI3K1E@YUZE*5*O2=JF#A*G33]DZ_L:,L=7Q$JE'"1Q5>C3HNG4
MHXQ+!>K>+_VNM!TC]FFW_:+\%^-]%\?>&_A3XE\$)\>)X_!_B#PQ?3^$[[^P
M;3QMJ=MX1\2G3O$_@<P>%_&FA?&_P;-K-M=6OB?X<+X<UO1KO6O!_C?1?%-Y
M]VU^ ?B+Q/\ LVM\"OBA\&S\7/BG\0M?_:?^(7PSB^/WQ'U#]F7X^>"K6U^%
M_@7PE\/?AWJ$>D^%=/\ A9<K!?ZI\'OA'HO@>2'19+ZZU7XB^,=2\8"'PMX1
M8Z=X0_2;_AX7^RK_ -#9\2/_ !'#]I3_ .=%7Y9QY1X%HX/!QX0QKQ]1\3<5
MN.)E16'KU.'9X7A6OEWURDL-@FG1XCQ'%F#R:K5P&78G$\.87"UZ^7X*+P]"
M/7@GC6J/UN'LY?4*/MHJ?M(+%K%334)W?.U0]JJL]/:J&$KRC3GB94,-]K45
M\4_\/"_V5?\ H;/B1_XCA^TI_P#.BH_X>%_LJ_\ 0V?$C_Q'#]I3_P"=%7YH
M>@'_  4)_P"36_$/_96/V7__ %J/X-5]K5^2/[7/[7?P0^,_P5;X:?#.\^*'
MBGQOXG^+O[-4.B:';?L\_M#63W9T_P#:3^$NK:A-+>ZI\++'3;&ST_2["^U+
M4=0U"\M-/T[3K.ZO[^ZMK.VGGC_6Z@#X1_X*,?\ )OWP]_[/N_X):_\ KS?]
MD2ONZO@S_@I&]Q:_LT:#K46E>(-7L_"/[8'_  3F\>^((/"_AKQ!XOU>P\'?
M#W_@H=^RWXX\<>(5\/\ A73-8UZ]T[PKX/\ #^N>)]<ET_3;IM.T/2-1U.X5
M+2SN)8]W_AX7^RK_ -#9\2/_ !'#]I3_ .=%0!]K5X%^T9\5M4^%7@KP_P#\
M(Q#:W/CWXF?$GX?_  >^'D-_:O?6$'BCXA>(+?2Y=?U*QCN[&:^TGP3X:C\1
M>/-8L8+N">\TGPO>VT4L;RAU\F_X>%_LJ_\ 0V?$C_Q'#]I3_P"=%7SQ^TK^
MUK^S?\4?!WA&\\'^*?'<OQ"^$OQ6^'GQH^'\&H_L]_M':?8ZCKG@76U?6O#=
MSJ$_P:N8].3QOX#U+QCX%&I,L2::_B9+^:>."VE)^EX.63RXIR-9^Z"RAXY?
M7/K3Y<&Y?5,S>!6/DFG'+99NLCCF<DURY;+'MM059QQQ/M5AL4Z'\=87%?5]
MO]X^KU?8;Z?Q-KZ.?LEUL_I/QU\;?BQX;_:]_9V^#$>@^'-+^%OQ/TCXX2:E
MJ]_*VI^+_%.H?#CP5X+\0Z?J6D16-S%I_A'0++4O$5YIDT&I#5M:\174%Q,+
M/PSINFV-QXG^9?A_^V/\4+O1O@Y^T9XH\6>&=5^"7[0_QL^-GPN\/?"_3/ 4
MMCJO@7PQ\/+3X^:CX$\4VOCEM=.I:QKNN:7\$[>Z\<6NL:')IB77B6XMO#5E
MID>CPR:GO^-OVG_V1?&WQL^!?QKN?B5\6-/U'X':=\5]/T[0(/V9OVBIK'7U
M^*VA^']$O9-0NY/A)]HM'T:/P_%/9BTW+<R7,J3G8B&O!_!WC7]D[PUXH\,6
MFJ_'GXJ^(_@=\-OB9\4?B_\ "KX.R_L?_'S3[OPUXU^+<GQ!?7+?Q%\08_AA
M=:EXJ\'>%H_BIXZMOA]X>L]#\,7^CVVJ6,7B;Q#XR&BZ9Y'ZUD&?>$T>'\%2
MS;*\KHYI2X3P.%SR"R;&UL1F>(H9AXI_VAA<IQE6&/6%XIQ\LR\+\PAGRJY=
MA:6793C\OI8C#4\'B,OS7@K4\?[=NG.<L/\ 6Z$HQ]I",E1^I9;!65J<U2HX
MNGFDJ\9SE.K]9H5)PQ"CR4.KT[]LG]IGPM\-_AS\3Y+70OCOKG[3W[%'Q^_:
MG^"_P=\*_#R_T#5?#GQ&^&O@/X;?$OP#\'M)O-)US5M<\<:+XKT+X@W7AR]N
MKNP_X2Z\\3:%IDVBJD?B-])TGM_A5^W3.GAR5_B+\3_!?BOPGH/Q@FT'2OV@
M_!WA"]U?1_CG\*[3X=^$O%7]O_#OP'\/KSQC>7FK3_$+4OB?\/\ 4;OPXNO:
M+X;\'_L[?&[Q_KTVEP>!?$,^E^5_ [XD?LO?"?Q?\,]>\3?M!_%?XD:%^S[\
M,?%/P:_9U\.3_L??'SPI)X$^'_BZY\$#4&\8ZMI7PQNE^(7C2ST+X=>$O"6D
M^)[?2_!UA:^'[;5C/X;N];U[4M9ET?B[\3_V3/B=]@\2V'QT^,7A?XKZ+\4_
M$'Q+T+XA2_LI_M >([:R@\2_"_QK\#+SP5<>$KWX46=A<^&=*^$/C_Q#I7AJ
M&VOM/FTWQP;?X@Z@VLWFH>+=)\5?39AQ1X&8S,\7DU;(\HAEN.Q,,5'B[)<G
MQN72P,7F?'D<HR^AET\LE5P]'+.%L5P-@,^QU/+\2L5G<,SS&KEG$V/RC"9G
MC(I8?,'[%U<36A[-THXB*E"I[><\'2I9EB:3<O=I2Q"J8C+,-)TU&I"%)_45
MB:^*I_H7/\:IM*_:,^'GPSNM1T+6? ?QW^$GB;QO\)];TEDEF3Q+\,+_ ,/7
M'C"PDU2VN+FPU_1O&'@[X@^&?$GA.YLTMVTX>$?%;SW6JVNMZ2NE?2=?C%X6
M^.?[*'AKXQ_L^7NE:[\0]+^#W[)'[/&J?"7X/07?P(_:7U3Q%K.O^,;?P9X5
MO[O4PGPG$EOI_@CX>?#+1M(MKS4UENO%&K^.=9N5MM.B\,P76M_8_P#P\+_9
M5_Z&SXD?^(X?M*?_ #HJ_"^,:?#=*KD$.&Z_UF*X=HK-*_LJ6'E6QD,\XKIY
M=7Q6'HU:]'#9MB>%*7"F*S_"T:]:EA<ZQ&)PZJU*E*O.?9@Y8R2JRQE.E2J-
M8*3IT9SJTJ=>668&684J-6<(2JT*68RQ%.A5<4JD(2FE%SG"G]K5\4W/_*1C
M1O\ LRGQ-_ZO3PE1_P /"_V5?^AL^)'_ (CA^TI_\Z*O,OA1\7?!?QW_ &\)
M?&GPR3QMJOA/PS^R-JGAC6_$.O?"OXI> ='M/$.L?&70=4TW18M1^(/@SPM:
M:AJ=UINEZA?"QTR:\NH+2U:XNHH(9;=YOCCL/TCK\Y_CC_RDC_9"_P"S&?\
M@HI_ZT!_P2VK]&*_+7]KKQWH?PE_;J_9'^)GC:R\9P> [?\ 9%_;T\"WGB;P
MS\-?B/\ $+3M.\7^*_C3_P $XM?\,Z!JK?#SPIXJFTB_U_1? GC/4M'35(K1
M-1MO"^N/:/*=.N5CZ\!*,,;AI2DHQC5BW*3225I:MMI)>;9\]Q92JU^&\ZHT
M*<ZU6I@*L*=*G"4ZDY.5*T80BI2E)V=DDV[;'VE17R'_ ,-U?LV?]!_XG?\
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MJ2"?^"9/_!1< $D_L)?M=@ #))/[/_Q"   Y))Z"@#[MHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** /A']D3_DX'_@J5_P!GW?#W_P!=D?\ !.>O
MNZOA']D3_DX'_@J5_P!GW?#W_P!=D?\ !.>ONZ@ HHHH **** "BBB@ HHHH
M **** "BBB@ K\H/ G[.GA+]I+]I3_@H5K7Q2^)?[6@;X>?M6_#[X<^!M"^&
MG[=/[:WP*\$>%/!@_8&_8D^(4NBZ%\._@;^T!\.? 6G+>>-_B#XT\4:E?6WA
MN/4M4UGQ'J5]J5Y=32AE_5^OAO\ 9,_Y+Y_P4\_[/D\ ?^NU?^">= %7_AW/
M^S]_T4+]N[_Q:5_P4W_^B[H_X=S_ +/W_10OV[O_ !:5_P %-_\ Z+NONZB@
M#X1_X=S_ +/W_10OV[O_ !:5_P %-_\ Z+NC_AW/^S]_T4+]N[_Q:5_P4W_^
MB[K[NHH ^$?^'<_[/W_10OV[O_%I7_!3?_Z+NC_AW/\ L_?]%"_;N_\ %I7_
M  4W_P#HNZ^[J* /A'_AW/\ L_?]%"_;N_\ %I7_  4W_P#HNZ/^'<_[/W_1
M0OV[O_%I7_!3?_Z+NONZB@#X1_X=S_L_?]%"_;N_\6E?\%-__HNZ/^'<_P"S
M]_T4+]N[_P 6E?\ !3?_ .B[K[NHH ^$?^'<_P"S]_T4+]N[_P 6E?\ !3?_
M .B[H_X=S_L_?]%"_;N_\6E?\%-__HNZ^[J* /A'_AW/^S]_T4+]N[_Q:5_P
M4W_^B[H_X=S_ +/W_10OV[O_ !:5_P %-_\ Z+NONZB@#\3?!/[#7P=OO^"@
M/[3?P]N/B-^VX?"_AC]CG]A;QCH\,7_!2O\ X*,6VKQZ]XY^-G_!171?$<M]
MXHM_VJ(O%&KZ=-I_P]\+IIFA:OK%]H7AZYM]5O\ P]INEW_B;Q-<ZO\ 8G_#
MN?\ 9^_Z*%^W=_XM*_X*;_\ T7='P]_Y2;_M=_\ 9B/_  3G_P#6@?\ @J57
MW=0!\(_\.Y_V?O\ HH7[=W_BTK_@IO\ _1=T?\.Y_P!G[_HH7[=W_BTK_@IO
M_P#1=U]W44 ?"/\ P[G_ &?O^BA?MW?^+2O^"F__ -%W1_P[G_9^_P"BA?MW
M?^+2O^"F_P#]%W7W=10!\(_\.Y_V?O\ HH7[=W_BTK_@IO\ _1=T?\.Y_P!G
M[_HH7[=W_BTK_@IO_P#1=U]W44 ?"/\ P[G_ &?O^BA?MW?^+2O^"F__ -%W
M1_P[G_9^_P"BA?MW?^+2O^"F_P#]%W7W=10!\(_\.Y_V?O\ HH7[=W_BTK_@
MIO\ _1=T?\.Y_P!G[_HH7[=W_BTK_@IO_P#1=U]W44 ?"/\ P[G_ &?O^BA?
MMW?^+2O^"F__ -%W1_P[G_9^_P"BA?MW?^+2O^"F_P#]%W7W=10!\(_\.Y_V
M?O\ HH7[=W_BTK_@IO\ _1=U\=_M-_L-?!WPO\:_^"=NB:/\1OVW(]/^(O[8
MWC?P=XJ2^_X*5_\ !1C6+J?0;+_@GW^W5X_MXM'U'6/VJ+_4/"VHCQ-X'\.S
MRZ[X6NM&UVXTJ'4O#=QJ4OAOQ!X@TG4_VRKX1_:[_P"3@?\ @EK_ -GW?$+_
M -=D?\%&* #_ (=S_L_?]%"_;N_\6E?\%-__ *+NC_AW/^S]_P!%"_;N_P#%
MI7_!3?\ ^B[K[NHH ^$?^'<_[/W_ $4+]N[_ ,6E?\%-_P#Z+NC_ (=S_L_?
M]%"_;N_\6E?\%-__ *+NONZB@#X1_P"'<_[/W_10OV[O_%I7_!3?_P"B[H_X
M=S_L_?\ 10OV[O\ Q:5_P4W_ /HNZ^[J* /A'_AW/^S]_P!%"_;N_P#%I7_!
M3?\ ^B[H_P"'<_[/W_10OV[O_%I7_!3?_P"B[K[NHH ^$?\ AW/^S]_T4+]N
M[_Q:5_P4W_\ HNZ/^'<_[/W_ $4+]N[_ ,6E?\%-_P#Z+NONZB@#X1_X=S_L
M_?\ 10OV[O\ Q:5_P4W_ /HNZ/\ AW/^S]_T4+]N[_Q:5_P4W_\ HNZ^[J*
M/A'_ (=S_L_?]%"_;N_\6E?\%-__ *+NC_AW/^S]_P!%"_;N_P#%I7_!3?\
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M%^%XO#>N>"M'\5Q"TOK3]H?Q6^OZ1JGA2::_N+'P]>Z=XCT2/2-2TOQ-G?\
M"R/^"AO_ $3C]BW_ ,._\=/_ )QU9_QQ_P"4D?[(7_9C/_!13_UH#_@EM7U!
M7T669;A<5A55K1FY^TJ1O&I**M'EMHM.KU/QWC?C//<BSR6 RZMAZ>'6#PM9
M1J86C6E[2JJKF^>?O6?)&RV73<^;_P#A9'_!0W_HG'[%O_AW_CI_\XZC_A9'
M_!0W_HG'[%O_ (=_XZ?_ #CJ^D**]#^Q<!_)5_\ !T_\CX__ (B7Q7_T$X3_
M ,(,.?+^K?%_]O?0-,O];U[P9^PYHFBZ5:3W^J:OJ_QM^-6F:7IMC;(9;F]U
M#4+WX)P6EE:6\2M)/<W,T4,,:L\CJH)'SQX?\3_M>?LV>+OCY\1/&FI_L"^'
M(OVJ?C]X;^)=M'X\^//Q1\$Z=I?B33?V;_@%^S[9>!O#NHZQ\*(4\4WNHV'P
M"C\8QRQ+97[2>)KG18=(EAT$:QJ_8?\ !4TH/^";W[<9E*",?LP?&/>9" @7
M_A"M6SN+?+CUSQ7%>!+WX=:/^U_^V+=?M'7G@?3M9O[+X'VGP,O/BI/H]II5
MQ^S>?@WX6'B'3/ EUXQ9-+?3A\>X_BW<?$/3_#\I+ZA-X<N/$UOY4GA]V_5>
M&/"+)<ZX,QO&6)Q6=5HY=F6<X*ID&1X:CB\XS*GEF&X'G">5/$*O&4Z57C-X
MS-Y5,!C(8'*,M6(IT9U<<ZV [(>(?%+HTZTL31GS^V7)2R[#-IQQ>'PD)/?]
MU%UO:5I:-.6'I1</;^TC]%R_&#]O:'5++0YO!O[#<.MZG97VI:;H\OQN^-4>
MJZAIVF/91:E?V.G/\$Q>7=EITFHZ='?75O#)!:/?V27$D;74 D?9_%S]OK49
MM1M]/\%?L/7]QH]\-,U>"R^-GQKNIM*U(V=IJ T_4XH/@G))87QT^_L+X6ET
ML5P;*^L[H1^1=022?DM96OB;6?V;_ASX*^"D<<'[3-Q^U?\ M">,O^"6UQ?R
M7VGM\//V>-)\?Z_;:;XZ\>M=66HZOI?[(\?PJU34_"^L:5J.ESZ5XI\ >*?A
M)X'\*V'_  F&K?#B6P_37]@?4_AW?_L\Z7:^#=-\1:)XST7Q/XGTG]H?1/B!
MJ%GJ_P 6]-_:3AO5F^,#?%S5[-(H]:\9ZKX@G&M6>NVT-OH.N^"]1\):KX*M
MK;P'=^&+:'U.-_ K+.#N',;GL<WQV9U<'Q)4X<J8"."I8>K2IPQ=6-'B3&J.
M88FMA.'LQ2J<+X"NZ%24_$?AKCOAAXVK@^'L)F.:3B?$3BJ@HVQ>%FY5*M-O
M^SL.HP]C6QM&,I-2E;ZXL)]9P,7I5PD,74<G+#P^L>A?\+(_X*&_]$X_8M_\
M._\ '3_YQU'_  LC_@H;_P!$X_8M_P##O_'3_P"<=7TA17XM_8N _DJ_^#I_
MY'+_ ,1+XK_Z"<)_X08<^;_^%D?\%#?^B<?L6_\ AW_CI_\ ..KE)/VB?VTO
M"GQT_9&\!_$WP-^RUI?P_P#C[\>/%OPH\6ZGX#\9_%OQ?XRL=/T3]DW]J#X[
MZ9)X<L_$/@GP%H>FWL_BSX)^&K._U;5+O7X$\.7.NZ9;>'6U/5-/\0>'OKNO
MD_X_?\G#_P#!-'_L]CQ[_P"NW?\ @H/7+C<JP=#"UZM.-13IPYHMU9-7O%:I
MZ/=GN<-<>\1YGGN68#%XC#2PV*Q*I5HPP="G)PY*LK*<?>B[Q6JU/THKY=_;
M)^+_ ,0O@7\ M:^(?PJT_P %ZKX_3X@_ ?P/X=L/B(FO'P9/-\6?CU\,_A/>
MG79?#-S;Z[900Z9XVOI[?5-.34I=)OHK74Y-!\206DOA_4_J*OAW_@HG_P F
MQM_V<5^Q+_ZVM^SY7S5-*52G%[2J4XOII*I"+UZ:2>O0_;L74G2PF+JTW:=+
M"8NK!M)I3I87%58-IZ-*=*#:>C2:>C9S3?$?_@H8&8#X<?L78!(&?C!\=,XS
MQG_BQPYQUX%)_P +(_X*&_\ 1./V+?\ P[_QT_\ G'5](MU/U/\ .DKZ]9+@
M+?!4_P#!TS^=GXE\5IM?6<)HVO\ <,/T;7Z'RY_PN+]O3^V3X<_X0_\ 89_X
M2$:8-;.@_P#"[_C3_;0T4W9L!K']E?\ "E/M_P#99OE-D-0^S_9/M8-MYWG?
M)63+^T#^VO Q2?2OV H763Q)"R2_M!?%R-UF\&J7\7PLK_!H,)?"B OXEC(#
MZ$@+ZHMHHS7QO^T7\/?'&O?\%#-2^*WP8/G?'CX"?L3?#?QOX \.R:F^FZ5\
M4O#U]\>_B_;_ !'^!OB63>+6'2OBUX=TV+2-!U^^ANK?P/\ $/3_  3X[:TU
M"'PW=:5J'QMX;^.D_C+X,>-[WP3JNJ:/\-OCKXI_X+?^+?$/AG6]#LM+UB\&
MAZ/J^LZ-I_B*RU6Q;6M"UOPIJ>I:E;ZKI]K=6)74$N;?4?MD$4./Z/R#Z-&6
M<19/DN<8#B.M4IX[).!\=G&&EAZ=+$9'F?%M;BC%3P,X.M7GB\'/AWA^.;</
MYC"A2HYICH9SDF/GE>*RRE6QGM4.-^)ZV)PM#^T<*EB,1DV'YO[.PO/&68X;
M+<1B[0YM9819KA)48R<8XBA.59RINE4@_P!M+;XH?\%!;RW@N[3P!^Q-=VEU
M#%<VMU;?&7XX7%M<VT\:RP7%O/%\$'BF@FB=)(9HG:.2-E=&96!,W_"R/^"A
MO_1./V+?_#O_ !T_^<=7Y=?#+]HGXVZ5\!])T7QQXMOOA3X^C\:_LA_#GQOH
MFD3>%;WP?^SS^R/\2M$TNT\(?'KX>^)-3T64>+)/'UK'=^$_&/Q0\6VK:%X&
M^*8\3Z):^'--T+X9V]UK73K\:?C)J_QS^&GP#\-?'_QMJ_PCU#]NO7?@;I'Q
MFT>;P!J7B[XC?#=?^"<_CO\ : \1^#W\9P^$KOP]KFH?#[XSZ8-./C3P]I-I
MJ]H=/B\-ZC>RZ[X?U>YF\[$_1BS+#XS.*$L\R>.'R>6>XBIC?^%K%8.OE&04
M,9B,5F&%Q^ P=7+L=6KT\/3>69?@\3]9SS"_7LZRA3R'+<7BZ7D4/$?BVK@Z
M6+GB\#!2P>%QE6,<!1ER1Q&'I57&DY*,JRC-UN622_V58/'5.3#9EA)/ZUT+
MP[^WWH7[1GQ5_:*B\+_L=7.J_%/X(_L^?!2[\+2?%'XVQV&BV?P!\>_M/>.K
M3Q%;ZLOP8>XOKGQ5)^TK<Z7<:7)86D>BIX+AO8]0U9O$;VF@^N)\6?V_)-0N
M-)C\$?L/R:K:6EKJ%WI:?&KXV/J-K87TUW;V-]<6*_!(W4%G>3V%]!:74L2P
M7$UE=Q0R.]M,J?FDW[2'Q4U6YT/X+ZO\</$FE7WA/QW^WQX>;QS?>,OAO\%[
MOQ9X:_9H^-_A_P !?#K5?&/Q?UWPIXMMM2\5Z!H&N6FD>*/!'@7X1ZG>^,GO
MI/B+XIU#PU;:58^'?%?N?[ ?Q9UKX\>/-!^-/BF?3[KQ9\4_^"<W[$7CCQ+=
M:;'#%97>LZ]XS_:3N]1O+**&"T1+&[O6GN;4)9V4?ER@I96>3;1<6>?1PQ_#
M?#><<39IF&&J8++<'BL10C@89CS8F;>5XC**DIX[#X>FL)FN68S&XQNC.>,R
MZOA*>#Q="4ZM6M!XOQ'XMP?)&>*P<YRQ+PSY<!0Y(5(5W2JKG:CS6@E5@XQ<
M)*7*W!JQ]C_\+(_X*&_]$X_8M_\ #O\ QT_^<=4UO\1O^"A+SP)-\./V,/*:
M:)9?+^,/QS63RV=0^QF^!CJ'VD[2RLH;!*D<'Z*J6#_7P_\ 76/_ -#6OPV6
M2X!1;4*ETFU^]GNDW^A-/Q*XJG4IP>)PEI5*<7; 8=.TJD(NSZ.TG9]'9]#F
M/V*OC+XL_:+_ &-OV2OV@_'MCX=TSQS\=OV9?@-\9?&>F^$+74['PEI_BSXG
M_"SPKXV\16/A>RUK5-;UFS\.VFL:Y>6^B6NK:UJ^IV^F1VT5_JE_=)+=R_35
M?!W_  2Q_P"48G_!./\ [,._9"_]9\^'E?>-?'O1M=FU]S9_1L6W&+>[C%OU
M<8M_BV%%%%(H^*/VKOC;\>?AE\0/V:O 7P'\/_"#Q!JGQC\6?$K2?$T/Q?U+
MQKH6GVNB^"OA;K_C2TGT#7O!6G^(+G3]6;6=/L(KB'4O"VM65_I;WMO'/I-X
M+>\/'?\ "R/^"AO_ $3C]BW_ ,._\=/_ )QU:'[4W_)SW[!O_8Y?M"?^J!\3
MU] 5]!E>787%X:52M&;FJLX)QJ2BN5*+6BTOJ]3\AXZXPSS(<YIX++JU"GAY
M8*A7<:N%I5I>TJ2JJ34Y^]9\D=-ET/F__A9'_!0W_HG'[%O_ (=_XZ?_ #CJ
M/^%D?\%#?^B<?L6_^'?^.G_SCJ^D**]+^Q<!_)5_\'3_ ,CXO_B)?%?_ $$X
M3_P@PY\W_P#"R/\ @H;_ -$X_8M_\._\=/\ YQU'_"R/^"AO_1./V+?_  [_
M ,=/_G'5](44?V+@/Y*O_@Z?^0?\1+XK_P"@G"?^$&'/BGQW^U3^UA\+9-/B
M^)U__P $X_AO+JT<\NE1>/\ ]IOXE>#9-3BMF5;F33D\1_"336OH[=G19WMA
M*L3.HD*E@#YK\0=4_;(^-GC#]D+XCVD_["*Q?"+XU>)/CA\.(M!^./Q6US3O
MB[-JW[+W[1GP%NM"T34H?A(J7%EI^A_';4/B!)J^@IK[-!X+;2Y+""SUB?7]
M#XOX]'XC_P##RKX5'X6?#;X1?%'Q,O[!OQN>?P_\8?B3KOPOT2#3E^/_ ,#F
M6]T_7?#WP6^.-Y<:@VH"SLC:3^&=.M([6YGO6U8RVJ6%W\W_  &\8Z_%#\(_
M#&F>,[OX=ZY\??VJ_P!N63]HKX,>%=-T;0KG]G7XB+^S+XQ\3WGP/\/3ZAI^
MH7-O)X#US1-!^(VD_$+2]/\ #]G\5;OQ(/BI:^'[7PMXWM]&/]!8+Z/>19CP
MGD^>8;/,5#'XWA?)>)\;AYXK+,92PU#-J7B7B:M&KE664*O$64X?!8+P[JXC
M!9QG4_[+XCQV,EP_EM7+\WCAG4]-<>\42E1@L;A(NH\'&4G@,//7%T,#6;M"
MT:3I/'0C"C6DJF*C"I.C*U*LH?I=X<^/O[;7C!+J3PCH_P"P)XJCL=0U;2+Z
M3PU^T!\7==2RU;0+T:;KNEW;:5\&KM;;4=$U%ET_5[&8I=:;?,+2]B@N"(ZZ
M;_A9'_!0W_HG'[%O_AW_ (Z?_..K\GO^"7/@JV\+^/?V4M3G^(_CJ]'B;_@C
MU^R)K.B^']?\0Z%_8.NWVI>)/'6I^)+32=-M]!TZYU=/"D=_I5^&M;NYO]*C
MURVN=>N[T:E9R']\:^(\6?"G(?#GC/%\,99F^-S_  =##JO2S+%8&ME-:<HY
MOQ;D]:C+#RJUJ<W2K\)5Y2K4*CI<V+6'<8UL'6]KY]3Q)XKA.RQ.#LZ6%K1_
MV'#R?)BL'0QD4W:-W"-=4Y-)*4X3<4DN6/S?_P +(_X*&_\ 1./V+?\ P[_Q
MT_\ G'4?\+(_X*&_]$X_8M_\._\ '3_YQU?2%%?FG]BX#^2K_P"#I_Y$?\1+
MXK_Z"<)_X08<^;_^%D?\%#?^B<?L6_\ AW_CI_\ ..H_X61_P4-_Z)Q^Q;_X
M=_XZ?_..KZ0HH_L7 ?R5?_!T_P#(/^(E\5_]!.$_\(,.>+?LP_'#]H'Q_P#&
MC]H7X4_'GP[\&= G^%?A7X%>)_"J_!_5?'/B&*ZM?BD/BI%JY\1>(/&VF>&7
MN;J&[\ 6PTW3M+\):?#IUK+++=:UKD^H+;Z+]PU\ ?L]?\GM?ME_]D>_8W_]
M+/VFJ^_Z^5Q=.%'%5Z4$U"G5E"*;;:2Y;7;U;U>K/WKA[&5\QR/*L=BI1GB,
M7@J5>M*,(TXRJ3E63<81]V*M"*26FG=L^)OVJOC=\>OAK\2?V;OA[\!_#_P>
M\0:C\7]8^*EOXGB^+^I^-M!LK;2? G@"3Q-8R^']>\%:?XAGL=3?5GM8[NWU
M+PKJ]I?Z:;F*&[TB[CAGGY#_ (61_P %#?\ HG'[%O\ X=_XZ?\ SCJO?M/_
M /)UG["W_80_:3_]5%!7T%7L97EV%Q>&=6M&;FJLX7C4E%67+;1:=7J?G''7
M&.>9#G4,%EU:A3P\L#AJ[C5PM&M+VE1UE-J<_>L^2.FRZ'S7+\3?^"A%O%+/
M/\/?V*8(((Y)IYIOC'\<HH888D,DLLLK_ ]4CBC16>21V5$12S$*":Y7P3^T
M1^V?\2]&_P"$C^'%C_P3\^(/AT74UB=>\#?M#_%CQ;HHO;<*;BS.J^'_ (.:
MA8"[@#H9K8S^=$'7S$7<,N_;HT7PQXD_9N\5>'?&'BWQ+X T'6O$WPTLYO'?
MA_PO8>-=-\(:@GQ'\+7N@ZY\1O">K7-GI7B#X/P:_::9!\6]*U6ZM=+O?A]<
M>((-2OM-L7N-2L_@+4/CWXV^$%Y^TAXA\56O[/OB/XB^'/V<- \0Z?\ M:?L
M=:'J"^$+SPZ?BG%X9\->!OBM\$?''Q)USP7X%\::;J7BG5_$'A/QAKOQF\9^
M'K?PK%XY\5ZD_ASP[X>U;PYJO[AP9X(X3C3AF>99;B\8\^K9O4RW!97-+#X.
M5&ECN%\N^M?6\3A94\SYL5Q116+P65YO@<\RRGA\/6H<.<68?,I5LG^9I^('
M%E2C"HL7@TY2U;P.'M&*KJBWR)>TE%+FFZD'5<9J-)X:$7+%Q_2G_A9'_!0W
M_HG'[%O_ (=_XZ?_ #CJ/^%D?\%#?^B<?L6_^'?^.G_SCJ_)FX_:M^-GA#Q#
M\7O -C\8O[2\-_![XT?\$N/$OB3QF_Q0\$?&2\\*_#?]I3]H37?!?QQ\.^-?
MB+I_PW\">'M.\,/X9\+V\5TJZ?J;>&-)UFZUNU\;6L>H1Z?X;]<3]I3QWX]_
M:(^+/PV/QXNO#7P!E_;%U#X;7'Q;\(ZOX(M$^'^@>'?V,_A!\3O#?PQT#QU>
MZ1J6@Z(/B%\4];\77]YK6L?VEK$T^C:EX1TF^M)-7@BM?H<5]%S/L(JN(J9E
MEDL!1R=Y_/&4J7$-62RQK)*U",<'3RQXB>;XW YW3QV79#"I_:F84\+7I8*G
MB9SH5I34\0>+:2;GB\(DG%?\BVCS/GJ2@N6&CG)05.O.,;RIT:JG44(PJ,_0
MK_A9'_!0W_HG'[%O_AW_ (Z?_..KP_XIZ/\ MY_%/XA_LT>+;[P_^QGHVJ?L
MV_&?Q!\=-+T.U^*WQIO'\7/KO[-_[0W[-TFBWS2_!JWN-&T^TB_: F\6#6K>
MVU,RW?A2'PZUC$-?;6=&^'/AA^TQ\2_B)X+^$G@S4_VD/$.L2Z]XM_X*!ZE-
M\5YO&/PK^!&D^+?"'P+_ &PO%WPM^&.LWGQBN?!WBS2[YM \(66D:+)\.OAU
M\)=0FUK0]3F\?>)==LK7P]I.C^*? [_X\_&3Q9X-M_VO="^)OBW1?C7XR_X)
M%?!7QW8Q:&_AR/P[J&O6GQVUNY^)'B;1O"-]X;>VNI]&\/-?>(M8-M:PVN@:
M?J<E]=Z3IEK)9VUK[6#^B1FU3&XC X_/\LP,XXW%91A:SP?$+H5<U>,RW"Y0
ML5]9PF$KX3+LQAB,TQ&+Q,J4L;DL,IE3Q^6^TQ#>&<_$#BVG)TY8S!.K[2I2
MC!8##INI2Q$J,UKJER0]I3O%.<ZN'HN-.=5.7[G_ /"R/^"AO_1./V+?_#O_
M !T_^<=5"7XN?M\P:E9:-/X*_8=AUC4K34-0T[29?C9\:X]3U"PTF73X=5OK
M&P?X)K=W=GIDVK:5%J-S;PR0V4NIZ?'<O$U[;"7\^_C/^UU\1&^.G[2_ACX5
M?&"POOA5X?7_ ()D>'=2\8^%+WP9XBTWX$^$_P!H7XU?&7PM\=_BA8ZJ+#5M
M/MM1N?!.C^&+9]9\42:IH'@E7T[QM-8PZ?I.HK>>+_'WXJ_$OPE\<_@UJGP1
M^+=_^T2/AM\*OV_/#7B[XN1^$HI/B/\ "CX(:?XP_P"">NL_%+6/ 47V!O!7
M[4OQB^%GA:^U6_\ "U[X:L+70-9U^6VT+7?#GB[Q3X+UCPEXN\O(OHN9KFE3
M+*6.S7!976SKAS$Y_@:6(I9W1AA&N&LLS[!X7/L?C,MPV6Y%B:V(S? Y;'+L
MPKX3-\SE7I5^'L/CHXC#-ZQX[XNYJD'C<$YQP[KQC#+\.W.\<'*G3IQNI5ZM
M3ZU*,</04\1*:PZ4.3&4)GZ]_P#"R/\ @H;_ -$X_8M_\._\=/\ YQU'_"R/
M^"AO_1./V+?_  [_ ,=/_G'5[5X+O]&U7P=X4U/PYXG_ .$V\/ZCX;T2^T/Q
ME_:-EJ__  EFD7>FVT^F^)#JNG10:?J1UNSDAU(W]C!#:79N3/;PQ1.B+TU?
MS_7X?P5"O7H3IXB,Z%>M0G&K]8P]6,Z%:M1FJN'Q$(5\/54J,E4P]>$*]"HJ
ME"O"%:C6A'S8^)O%4HQDL5@FI1C).."PLXM22DG&46XR34DU*+<9)J46XM'G
MW[''QF^+/QI\%?%"^^-.C_#G0_&WP^^/OQ3^%+V/PLG\3WWA0:+X+U"QBT29
M=5\7+:ZQK&JS6-]&VKZDVC>';.:]\R.RT.UMX4FN?KFOA+]@[_D#?M1_]GI_
M'[_TK\.U]VU\96BH5JL(Z1A5J1BM[*,Y16KWT2U/Z&RVM4Q.79?B*K4JN(P6
M$KU9)**=2KAZ52;45I%.4VTEHEHC\JOA3^TM^W=\6])^('B7PK\/OV1KGPQX
M>_:/_:[^#_AJ[\1>._C-X1U^\\-_L^?M7_&GX">'+S7= TSP%\0-.MM<NM!^
M&NG3ZW>Z?XIN+#6]6DO==L=(\)V>IP>$="]-_P"%D?\ !0W_ *)Q^Q;_ .'?
M^.G_ ,XZN&_84_Y(Q\2/^SY_^"H'_KS#]KBOLFOIL+E."K8;#U9PJ.=2E"<F
MJLDG*2N[):+T/Q'/O$#B7+\[S; X;$8:.'PF88G#T(SP5"<E2I5%&"E.7O2:
M3LY/5]3YHNOBE_P4#L;:YO;WP#^Q-9V=G!-=7=W=?&7XX6]K:VMO&TUQ<W-Q
M-\$$B@MX(D>6::5TCBC1G=E520RQ^*O_  4 U.RL]2TWP)^Q%J.G:C:V]]I^
MH6'QH^-UY8W]C=PI<6E[97=O\$9+>ZM+JWDCGMKF"22&>&1)8G='5CV'[2>T
M?LY_'_?MV?\ "D?BOOW8V[?^$"U_=NSQMQG.>,9SQ7XA>!OB[\:M$_9N_:'\
M2^$?C?XR\*:;^QK_ ,$MOV*OV@/A!X*T2V\%-X0?QJG[+_Q;\;:U:^-(;[PO
M>Z[XF\)^,+KX=^'+#6-!EUZSMX[*WGGT:;3KZ4W2_LO /@72X_X?QF;X'.*&
M5XC"<5Y/PTZ68TLPK82H\]CPO@,MJ1JY=2KXJ->MQ#QED6!JJI16$PN6RQ^9
MU:E2>#C@\5AA^/.+L52ISI8S!>TJXGZK3IRP&'BIUJD\-1P\%-^Y#VM;$<LZ
ME5QITH\DI-ISY?V1C^*'_!066:>WB\ ?L327%J8A=01_&7XX/-;&=/-A%Q$O
MP0,D)FB_>1"55\R/YTW+S4W_  LC_@H;_P!$X_8M_P##O_'3_P"<=7Y4>./B
M'\3O@[\3?V[?$?PV\3^*[S5OB=^V9^Q]X?\ &T.H^-/!^CK\+/@WX_\ V5?@
MQ)KGQ!\(:AXLT8^'_!BS^(!_PJS1O'?BZ+4?#&E2QV49#:YH%Q<2=7X7^-_Q
M_P#&/CW]G?X37GQ@\2>'O!WC7]L_XM_!F3Q+X7\6_#_QW\0_$'PS\/\ ["OB
MWXS?\(UXD^)^D> 6^'&O>(O"OQ;L;D6OBOX91W]S8:/IFE^&/%>K0^/]"\8V
ML?TM7Z,6)>"IYMA.),HEE4LKH9I4K8R.:T<;2H4N"<#Q=G/_  G86&,K3G@:
MM?&9;E]%5*5;.L/@_P"V\+4HX"5>EAXEX@\5*$JL<?@I4535:,O[-HJ<J$L/
MA<13J.G9N$YQQ$FZ4I7I0A3J5)<E>G*/Z6?\+(_X*&_]$X_8M_\ #O\ QT_^
M<=7SC^SG%^W;\!_#GQ"^&EDW["7C8ZC^T;^T9\7H;=?BA\9] UWPA-^U'\;O
MB%^TRWP\\16D?PY\1MK.L>']4^*&OVVC^)%M?"3>)_"<&BWR^"]+FM[R\U'Y
M9UKX]_&BU^']IK&M_'N]O=(^$GC']K7P5KNC^%OBG\$?A1^T3XVT[X&_'C7_
M  ;X1^)\=A\3/"MYX%^)MMH'@C0(] \4^%84\(VOB+QG?6VH7/VY]433-.R/
MB!XZUGXT_M&?#F[UCXH_$?P?X#\&_MQ_LR7OA#8?#7P]U;PUHOQ1_P"">GB+
MQRNG>,H;[PR[6NKZUXKU1+2XTC7RT]MJ?B35?#.G+"+G3K6TK!?1CK3J8F68
MY]A:. PN"SS$U\PR_!9YC8T<1E-'$XG"X..%KX; XG&8G-,-_9N)A0PE.V$P
M^8N3S',<7@<3ERQK>(W%="#J3QF#<8JK'FA@<.X>UHUL10J4W]KW)4'.4G&"
MC2G&HH3A+FC^I?\ PLC_ (*&_P#1./V+?_#O_'3_ .<=1_PLC_@H;_T3C]BW
M_P ._P#'3_YQU?.'[,/Q:^,WQ*^+\/PB\;>*K@:S^R/X0\;^!_VF FG:;9S?
M$SXK^)/%.G67P"\5W$2V9.EZ/XJ^!6@7OQUET[19+:![CXM^#[&X>";PYJ>D
MK^C]?D?%WAU'@W-HY-F&(PN+Q4L%A<QY\OQ.)JX?ZEF3Q&(RC$1JUJ-'GIYO
MDJROB'!.$7_PDY_E#K>SQ<\5A\+%7Q(XLI5:E*6+P4ITI>SJ<F!P\HQJQYO:
M4^:R4G3?LU*4;TY>VING*4>9KYO_ .%D?\%#?^B<?L6_^'?^.G_SCJ\J\'?M
MC_M,0^+_ (T^#?BOX7^!&CZU\./B/HGA;1K?X='XA>+-+F\/ZM\%_A'\0UN=
M4UWQ/>^![N\UIM>\=:] 4L_"^F6%KH\&CV@-]>P7VHW?W+7Y2>(O^3A/VK?^
MRO\ @;_UEO\ 9TKX3-LOPV#PJJT(S4W5A"\IRFN5\U]'I?1:GV7 ?&&=Y_G4
M\%F5:A4P\<#B*ZC2PM*C+VD)4E%N</>LN=Z;/J??G[#/_(D_'S_L]?\ ;*_]
M:!\;U]KU\4?L,_\ (D_'S_L]?]LK_P!:!\;U]KUX!^N!7S3\1?VN?@C\+_B'
M>_"CQ!>?$S7?B'I?A70O&VL>%OA;^S_^T!\;K_0O"OBC4==TGPYK/B"3X,_#
M#Q[9Z!;:YJ/ACQ!::4FLW-C<7TFCWQMX9$@9J^EJ_%'XX2W?A;_@HG\;?$>M
M?M#?M/\ [,'ASQ#^RQ^S'I6A^*?@=\#O OQ*T/XA:KX?^(7[2T^NZ1J.M_$C
M]DW]I+2[;4O"%OKNBW+:=X>U#PK=)!XDAGUFRU>.73)]._4O"?@[)N-,YS_!
M9W+'.CE/!^;Y_@L-E]3,88C'YC@<QX8P=#"<F395G>=5Z3H9UC\34H93E>*Q
MDE@X5)JE@J./KT^7'5IX?"RK4TG-8C!4?>2<8PQ.*E1JU'S2A!>SA%-2J3A2
MBY)U)J]-2_8SPEXHTSQKX:T;Q7HL&OVNE:]8Q:C86_BGPGXI\"^(H;>;.Q-7
M\(>-]&\/>+?#UZ,'S=-U_1-,U&#CSK6/<,^2?$K]I[X*?";7W\*^+_%.JS^)
M;.PL-9U_0? _@/XA_%/5O!'AS53J(TSQ?\2K'X7^%/&%Q\,/!&H?V/K/V/QO
M\0X_#/A*X&BZRT6LN-)U$VWYS_'C4/'?]M?#/2/A1\0/BQXX\,_\%!OASX3_
M &6Y/'FL:=<>&?$GAWX@> K[7?%'B7XSZEX:MM!^'6G?#S7O$/[-!^/VJZ[?
M>$_ G@RRO/%/PO\ AWIMCI&E37FALG:^&=7\5_LS^)OVQ?"WB[5M;^'GC3XS
M?M'6'Q2^#'QH?X!?$/X]>"/%7PZUSX?_  V\)>'O"=Q8?#>ZAU:Z\5_#[3_A
MWKGP_O\ 0/$_B+P[J&GP'PWXLTN/5]$UNTAG^OP7A%E,:*S/%9G/,I9EAWC,
M@X.P6*KY3GN(PU#BM<)<0U<?B\9EV:9I1I<%YC#'?VIA\-PWB,]S##8*CF<,
MJHY;+.5EO']?J6=/EBIP5!U\3:$Z5*CB,-7Q-#$N%.;HVQ$<-6I4H2Q/L*5>
M*6(JPHU*-:K^I/A_Q!H/BS0M&\4^%M;TCQ+X9\1Z58:[X>\1:!J5GK.A:]HF
MJVL5]I>L:-J^G37.GZII>I64\%Y8:A8W$]I>6LT5Q;S212(YUZ_G)UJV_:SU
M72_@1>_M > _"GPT^' ^!'BF'P9\/_"GP5_:+T+PAH/QNC_: \>QZ%K=C\,O
MV=O'E]XH^%_Q0U?X(CX*>(? 6F>._$=]+X7\0ZE\2=/\(7_A'7+7Q=:W%GQ_
M\./V@M3^'_[=7CWQG!^T!XH^.OPC_P"">7[+'CKX&>)!IGQ#\-Z@/VG_  E\
M(?CQJNN>(O ?P[\)>*O%G@I_BS+XNM_#EKXVT'PCJ7C2^DN+NT\,:CJ.JZ9?
MVT%U]"_HY9>L5AJ53Q/X8IT<;F"P%">"J8+/:5.KC>-LEX,RZG_:N"S;*,JQ
MZR[$<09?B.*\;@7##9;2H8ZKEV&Q6'C3J4H_M6I:48X.K.K&G"4>:]"%64J>
M)J<RYHUYTZ$WAI4Z,W[1SJ.[M2=.4_Z+:*AMG>2W@DE&V1X8GD!4H0[(I<%3
MRN&)&T\KT/(J:OY>:LVG:Z;3MJKIM.SZJZT?56?4]:G-5*=.I%-1J0A4BI+E
MDHU(0FE*+UC)*:4D]5)23U3"OBG_ ()R_P#)CO[-/_9-=/\ _2Z_K[6KXI_X
M)R_\F._LT_\ 9-=/_P#2Z_I%GVM1110 4444 %%%% 'YS_''_E)'^R%_V8S_
M ,%%/_6@/^"6U=I\;?VAOA9^SMX?/BSXMW_C+0_"D&EZ]KFJ^)_#WPD^+WQ(
M\.^%]"\,6<6H:_KOC?6_ACX$\9:9X#T/3+"4WL^L^-+G0=,:TM[^XANI8M-U
M![;B_CC_ ,I(_P!D+_LQG_@HI_ZT!_P2VK#_ ."@>BZUXC_8/_;2\/>'-(U;
MQ!X@U[]E/]H+1M#T'0=.O=8UO6]7U/X4>*[+3M)TC2=.AN=0U/4]1O)H;2QT
M^RMY[N\N9HK>WADED1#^M>%>793G/$O"62Y\L1_8^=\69'D>95,+F-+*L1A<
M)GF?9!DM?'4L?B,)C<-AY9=2S>MF-\3AWA:BP/LL55PV&GB,3A_Y]\0:5*OQ
MI0H5FU2KX7+*,YJ2A[-595(.I=V5J:E*5I.,7;WI1BFWZ+X%_:5^$'Q$U7PK
MH.@:MXPTS7?')\4MX,T/X@_"+XP_"36O%-MX*TGP]KGB?4M TCXK^ O!6HZI
MHFEZ9XJT&X.O6=M+HMY)?&TT^_N[VSO[>U]X )) !)&<@ Y&.N1VQW]*_-KX
MU_![3_BO^T-^P#H_C7P9XA\1^!-(^%/[2L7C%85\6:=H.G7NH?#[X/:?I&F>
M,M1T&?3X+>/4IH]273]#\0W:6NHZGIOVFWLI]2T6":S_ #_D7]I35-"^#<GQ
M@;Q&OPDT3X4_%WPGX*L?''@?]I_Q/XDMOC%X4_:4^)_AOPYJ5]'\%]8T7QY'
MX^C^!VE?"M/A#XK\<W%T=50>+-9T36[/5K^]U'4_W/+O"#ASBJCE>-R+BJCD
M'UG+<1F&8Y/G>)PN;8JDY9YQQE>78+(L90K9;B,YS'$X?A".+Q.!QN4Y7+#4
M,55Q=/%5J$<+3K_GU##0Q%#!5U.%#ZS@<%B:M.4V_8UL7A:&(G27.U-T\/[=
M^UG4=.K3IX>M.I!3M&/]#5_IUCJMC=Z=JEA::GIM]!):WUA?VL-[87EM,ICF
MMKNUN8Y;>XMYD8I+#-&\<BL5=6!P<GQ%X/\ "OBV&QM/%OA7P]XHMM,OHM5T
MRV\1Z%IFMP:?J=NC)!J5A!JEK=1VE_ CNL5Y;K'<1([JDBJS _B7HGA/X]VZ
M?M@_$?Q_X<^/OQ ^-'PY_8(_94N/AM>6,NO_  \\17GQKO?@9\<=*^+VI?#7
M1=-U7XE?#[0/BK=ZI/IC^+K?P6OQ-UC1]:70['3Y/$^J6_AE+SPKQGK?B?PW
MX?\ CKI7AVX^*.E_ K5;3_@G%XDM=<^$G@/]I'X1:;J'C[Q#^V/<>#_C59_#
M/4?B'XFU'X@ZOXUU7PI8:+9>+E\.WVCZY/92:1;7>FWVJ7,=_<^GD_@%7QN.
MJ87*O$3+WB,!B,AIO'9=0J/"RQ>>8' XO$_V34PO%6&Q^(K4\NS7"0P'N97B
M<ZJ4\SP:^K4L#B?JF=6DZ&'EB%*I)0@VX0Y5-+ZG3Q%>%G-*_-6C14$W[2E&
MIB:D(4DZ</Z/3IEA_:*:L=.L_P"UTLFTV/4S9P?VDFFR31W+Z>EZ8_M2V,EQ
M%%</:+*+=YXHIFC,D:,%MM-L+*?4+JST^SM+G5+F.\U6XMK2"WGU&\BM;>PB
MNM1FBC22\NH[*TM;*.>Y:25+2UM[97$,$:+^#WQ)T3XK?;=:;X%6VN:3^P(_
MQY^'UQXET+QOX2_:'U*WO+"+X"_%V'XBBU\':=-I/QI'P$N?C,_P&?6+3P8+
M;1;GXB6/BO4+W2K_ ,%W7Q$GO_0?A)J/Q:^'/CW]DGXC_$O5/BA??!73_%?[
M9'A*SNM/^&_Q=MM%T3PQX_7X777P%T:Y\&76O?$OXF7_ (&67PWXYL_AGXN^
M+%EH6NZ=IEUI>B2Z!X9L;C1([[R<5X'5*>3_ -HX?CO*L3B*V!Q]7"Y!*C6A
MG+K9?DF+SS"\*9A@X9O6H8'BY5L)5IXGAY8K&T,!3Q&%QF&K8G$8BIA*6M7"
M\GM$JWM.252+_EG&C9N5.4I<LUAX>U>):TP\Z4Z<7**E,_73Q#\1O!GAC5KC
MP]JNL-)XG@\$^(OB,OA'1=,UCQ/XROO!?A2ZTNPUW6]'\'^&=/U?Q-KJVVHZ
MWI.F6MAHNE7^J:MJFH6VF:/8W]_)]G';(WF1I*H<(ZJPWQR1, ZAE#QRJDD;
MX/S1R(DB'*NJL"!_,'%\._B?#^S_ .'OB+X@\!?&N+XWZS_P2._X*%?#OP7X
MBO?#7Q4D^*5I\6H?B%=>(_"'A2Y>*UF\0^'O'D_AB^O;KP;;ZVFGZQJJH;7P
MW+>W=A!!;_H9X0M=4L_VC?'-Y\6],_:6O/CK-^TIH?\ PI?4?A;9Z]/X3M?V
M4Y_AIX$LM&@U>^\5>3\([;X0:=J)\47WQIT&69?B1>?%&TU/4M#TG5M>?PO+
M=>CQ-X#97DV$QU3+^-:&:5\HIYA1QL</A,#BJN8X_+<7Q!@<7B<HP>&XFI07
M#."J9-AL1FF;XG,*N-RRAF%)SP691J87VQ5PM.'M.6M"485ZU",^:ZG&E3O]
M8G96IX>I.G4A1G"-24ZE7#T'%U)2D_UR((P2" >02",CU'K7R=\?O^3A_P#@
MFC_V>QX]_P#7;O\ P4'KY5_8734?#?Q8\0>$;#2?$?C[19?A=;77BOX]:SH?
M[1GPJ\47OC;1-6T*R72?CG\*?C'.W@36/C!XX74M;\32^.OAM'!=:7#H.N^&
M]6T70=%N/#\5U]5?'[_DX?\ X)H_]GL>/?\ UV[_ ,%!Z_#O$SA3_4O,L?D<
M<QAFM*.78''4,=&A#!RKT,="I.$JN ^N8S$X"I?#SDL'F,L/F-*C5PTL7A*4
MJM.KC/>X0@J7&&44D^;V68*#>FO[BM):IN-^5QYE&3Y)-TYVJ0G%?I17P[_P
M43_Y-C;_ +.*_8E_];6_9\K[BKX=_P""B?\ R;&W_9Q7[$O_ *VM^SY7XS2_
MBTO^OM+_ -.TC^F<P_Y%^/\ ^P#'_P#J#CCVMNI^I_G7.>+?%_A3P#X:UCQE
MXY\2Z#X.\(^'K-M0U[Q/XGU:QT/0=&L4=(S=:EJVI3VUC9P&62.%7GG0/-+%
M"FZ61$;HVZGZG^=?&7[;7@GQAXJ\%_!GQ'X7T#5_&VE?![]I_P"!WQH^(?PZ
M\/VG]I:[XZ\ >!?$-S)J,&C:1YL)UW5O .NZAX<^,NF:!"[ZCKE]\,[?2]#M
M=0U^ZTO3KO\ 9>$LIP.?<29+D^99@LKP&88SV&)QO/A:<J<8X/,<33H4:N.J
M4<!1Q688G!8/*,'7Q]:E@*&.SG!5\=5IX.CB)/\ D"E"-2K*,KNT,1.,(M1E
M5G2HUZM.A"4KQC/$5*<*$)232E4O:4N2,_7OAI\<?@U\6/$6J67@S5IX_'>F
MZ+;W>H>'/&G@+QK\+/B2W@]M1G@L-?M_"'Q1\+>#?&^I^ +G5WNH-*\5Z?I%
MYX.OM2:XBT_59[II%/JC>&/#F&5O#FA[99-9F<-H^GXDF\1,Q\0S,#;8:776
M=SK4AR^J%W-^TY9L_D;^U]J^O?M)ZUX=\?\ [.NE_$F>T^ 7[._[<.I^+_B!
M'X#^('@:^N;[XC? 6_\ !/@SX/>"E\1>'M!\7>)_&OB;X@6_ASQVVF>%+"[L
M](?X8Z1>:K?VNO7G@RSU/R[Q1X _:'\ ^"[W2_V>--^,FF>)_B3_ ,$W/"'B
MSQ[)'JGQ#U+Q!JOQ?\,_$'X4:7XLU#2-=\1WU[?:3^T9J7PB\0_$S3]#^SZE
M8>-=7UVST&?Y+[0;2]M/VO#^#N7YGA<EQ6%XSI<&9CG*I8;%<,<48VGB,1PO
MB,+4I5:T<_SK#YID]3#8.IDV.PV<Y12Q&24\>OK-3 XVGEZKX3%3[)89<R<*
MK@W"%3D4E.<)Q]G&>&BU43GB*<JE&E1C*=)RG.E3J3HU.=8?]QYO#N@SB>.?
M0=(F6[T<>'KF.;2[*07/A\";;H4ZO 1-HP%Q/C2Y UB!/-B#]Z^[D8[OX8^'
M/$O@OX7VUIX9T;Q$FA^(O%?@+PE9:';6:Z?H?AJ32]!\2:KX>AM+!-.T9-//
MC/3M,NA;26=Q+!KLD$4<UO->!?RF\0P>!6N/"MK\,?#?[2\?[#D'QTL[S]H.
MPUG1?B4GA*^TJ7X%_$BTTNS^''AF0?\ #0LWPXM/C):?#[4/CS:7.A+X7U3Q
M[?Z-J.E-J^A2?%PQ^<7'AW]J-]%\<ZE\)])^)L6HVGPI_;[TW]E+4]?L/%:>
M+=&^$>J?$3]FZ?X9Z+!JGB:,^)-)\2:GI.F?$2?X+Z=XSN[7Q4FCVOA<1PV]
MEID4=GGEW@U#%4O]LXZ654<1";HTL^4<BIX#&XBM1R?!8;/>;BK.*>#SG*EC
ML1F_$F24Z%3$83@K%8?,<+F=.69XC*J$_55%NG[>'QPIPM->S?MG"GS02Y54
M]A2A['&03I>RKU<!AW*4)MX;]O\ 4/!'@[5&L#JO@_PQJ3:9K;^)M+.H>'M)
MO&T_Q)-,;F3Q#8?:;.4VFN2W#-.^KV_EZ@\Q,K7!<EJUK/1M+TQE;3])T_3F
M2SMM.5K*PMK-DT^SDGDL[!3!#&5LK26[NI+:U!$$$ES</%&C3RE_Q,\0Z3XC
MG\5^(E_9DTKXVZ;^QY-IW[.(_:/TFXTSXYZ=XBU'48_CIK1^,H^'6G>,H4^)
M-SXD?X6+&O[0EUX$B\_7_"DMDB7FK>+!=(N!H7B;3_A7+^UO^T9\*U^,:?"'
M]DS]ICX5?$JU\$ZS+\3D.J_L]ZM^R'\*-,^-_AKP-X)^(-];:G+X9T[2O$NH
M_%#P=X5NK&TAA\5^$K4>&+"S6_LHKHCX)XW&X)1H<9UJ]>K0RQY?D^*R^M&K
MA,SXAS?+\BRKA;B2E_K=BZ'#7%&;YYF&4_5\N5',L)6RS,,LS?%9A0=26'P4
M3P\W&*4Y5)2E2A3C)KE<JM&>)=)3E:/MZ#A6ABZ=Z<*&)2A[5NHYK]X<$=1C
MO^'K4L'^OA_ZZQ_^AK7@/[,G@_Q?X)^"'@C3OB)>W]_\1=<BUGQ]\07U"]EO
MYK+QO\2O$&J^/O$^AV\\DTR)IGAK5O$=SX<TBVM3'86FE:39VUC;V]I%# GO
MT'^OA_ZZQ_\ H:U^#9S@J&6YGFN78;'4,TP^7X['8&EF6%C*&%Q\,'6K89XS
M"J<IR>%Q%2A7J86<I-U<-]6Q"M'%0C#GHN+KT7"2G!UZ;IS5TJE/V\/9U$I1
MC)*K35.JHRC&48UHQDE*,DO ?^"6/_*,3_@G'_V8=^R%_P"L^?#ROO&O@[_@
MEC_RC$_X)Q_]F'?LA?\ K/GP\K[QK\I>[]7^;/[(I_PX?X(?^D0"BBBD6? _
M[4W_ "<]^P;_ -CE^T)_ZH'Q/7T!7S_^U-_R<]^P;_V.7[0G_J@?$]?0%?79
M%_N4_P#K_4_])@?SSXI_\E)1_P"Q9A?_ $NN?+>F?MH?LY:OXEO?#-GXS\2K
M_9OCW6OA=?\ C&_^$/QHTCX16GQ$\/>(;GPAJ_@R?XYZM\/+'X+)X@MO&%I/
MX.CL/^$_\V]\7B/PM8"YU^XM].E^C](UFTULZF+*#5XCI.L7VAW8U;P_K^@&
M6^T\QBXFTP:]IFFG6](?S5^Q>(=%_M#0-3 E_LW4[OR)O+_G0AT'XD3_  C_
M &@/AWX/^)_[0]U\8KG]N']H3QIX'_8U\3_L^^"[S]GKQ_$?VU_$/Q"\-3>+
M?&6K?LOV_P 2#\//&?AV.V^(6K^)+3]I6"SL[.X;4]$E.BVMIX+D^E5L?%9^
M(GBU_P!H+2OBUJ'[*S?M>?MFR^,K :5\5=4M9]8G_P"%/']G:_U72O"<$_BK
M4_A!&B?$K_A&)-(L[SP+;^-7\.WUS''=VVD7=I_8'$W@3PSAO;O).)*M!X2+
MO@L;5EC\YS>G2PF0XRE6R#+,52X>6;8K.GF68X+*HY=C,5PUB\=@/JF69U7Q
M6$S6$OB:V"I15:5.=U2J2I^SA+GK6CCLQPL9.$YQ=I4<+1Q,YN*I^RE6K8=5
M*$8N7ZU>./BW\-?AL=23QSXST3PY/I'P]\<_%?4+*]N'DU*W^&_PS32'\>^,
MQI=I'<:C/H7A7_A(-#CU6[M[67RKC5].M462YNX8G[NQO;74K&QU.QE%Q8:E
M9VVH6-RJNB7-G>0I<VMPBR*D@2:"1)%#HK@, RJV0/YS_B)\*/B'J>EV'C/X
MF?#[XI:[XJUS]@'_ (*Z?"7X,:SK?A_Q[XD^(,7A36OB;H^N?LG^ O&5QI\6
MJ:U8?$/4OV;VO4TQ?'\D7CK6[R"^T[Q#>ZE\1+:ZA'NOQ-^'7QS^&'_"S? G
M[,>E?$/PQX?\1?LJ_L?^-_%" _%#Q);W6O0?M&ZUHW[1-UHM^^KR>(V^)NK?
M &'4;7Q5IG@K7=,^)^I:9!IE_P"'Y8/&B>&KYN+%>!'#?U?)\'@O$3 PSK&U
M9QQ6/S&.5T^%.3!XEX3-98?&X3/*V/H_4ZN)R^%!8BAB:F(S"&:915=+ZMA<
MUQ&-3"0C.I"%6,_8T76G*+Y_;0C*-&3PW+=5'4K\RPU-J,JU&4*LI1E"5.I^
MW9TVR.H)JC6%H=5CLY+"/43:0G4(]/GFAN9K*.\,?VE+.:X@@N);99!!)-!#
M*Z-)%&RTQX=T%;V;5!H.CKJ4UXU_<:D-*LA?2Z@^F1Z(][->"W^T27C:+##H
M[7+RF<Z5%'IQ<V:+"/P/'@SXG>*-)\%^'M#7QOJ?[/\ X@_;5_9,L;7PI\,_
M ?Q[^'GP[T_PL-)^)5I\;7TB]^('CC4?B])\/=94>#XOB58:IX=\&_"2PUZ"
MYN]-O/$FM^)?&T]OMZY+X^\-_''PO?>"?"7Q'T#QUX)_;K^%'PJ@T3_A!?CM
MXS\6:9^R;>^-]-\&WM]K'Q.272O@QI?P%U7P?>-K&A:18>&O&2Z'I]WIW_"4
M^*+CXCG7O&6D<R\"'[2IAL-X@X&>*_L[.,3*BL/["G@\/ELW2PF!S><^)*-;
M!U9XY8G#YC2AE\L#E<IX6K"I6EF%.G5=7"^R]KRU75=.E4J?NVN5^REC%"#E
M*=E+EP52*NT_;SIT*492E'G_ '0C\+^&X+C1+V'PYH<-UX:L+C2O#5W%H^GQ
MW'A[2[N&U@NM,T*=+99-(L+JWLK*&XLM/>WMIX;2UCDB:.WB5-S!XX//3@\_
M3U_"OY^/V89/&OB'PE\%M<_9ZF^*&H?M)'XH_M@+\9/%7Q)F^+U[X-O/A7;Z
MU^TYH_@'3M5\0>*Y+KX9:MH=G\4[;X21_"_2=.FOSHME8:B;6SL+&/Q+%+QG
MAWP)^U)XI^!GQC\,>#=0\9CXP^(?V OVC/#OQ?TGPWX$_:$\,Z_XG_:7U;X7
M^&+;P%=^//B!\8?'\6CVGQNM?'C^((/!>J_!K1?$46L65_XD@U'5O#?A?3O"
M-PW5BOH^1AF6.P.8^)F2X#^R\VPF3XB6>X7$83&8*&(X@HY9B<YQV7U,]S">
M7\-XEXW$YCDF8U,?2>;U(XAXS"Y8ZU;%3N."C4K2I/$)<N+A@HRDEI)XVM@D
MIKVG+2;E3E5ITY5.2-*4G4JP<96_H8\4^+/#7@C1V\0>+M;T[P[HBZEH>C'4
M]5N%MK0ZMXFUO3_#?A_35D;[][K.OZMIFD:=;(&ENK^^MK>)6DE4&[I>L6FK
MS:O!:0:O%)H>KS:)>_VIX?U[0TFOH+2SO9)=(FUO3=/A\0Z28;^!(M?\/R:G
MH-Q=I>Z?!J4M_INHVUI^ _[3W_&2WB+XIZE!X,^,GC;X*:+^SQ^PAK=Y;ZY\
M-_C3H7A]_$?P_P#VT=<U7XO3:-X>U30='U/6?&7A7X=PW]QXOM= TN]\2IHJ
M6Q,-U&-/8>FZO9>+;GXQ^++WXRZ9\7+W]CJ7]L']H*\\;6-OI?Q;NK*YCN?V
M=_V9C^SC?RZ)X0M7\:7WPEM?%$/Q-2R&BV=QX-L/B8=$N-5MXM=L[:YLN.'@
M/A(Y'@,1B^*/JV?U,OJYGF>4RP>"G7PK<:&)P7#N5X&/$$<5F7%V,P\,92IY
M5CJN6T:V(JX!X>I3_P!IIU.6E2C54+\T&\/0K33UJ*=;#TL1.C"%XQD\.J\:
M6(<I1G2J4:UZ:TA3_<#!.< \=>#Q]?3\:2OP[\>-K&@7OP7\>:7X>_:%^*_B
M_3OAO\)4^'7P)_:+T+XV^%OCX(?"UQK?G77A3X\? [4Y?A5H'Q2^(%C>>'K[
MXHV'Q0$[7%MI%GHGQ4U;2(-6UC3-!_<3)/)&">2.#@GJ,K\IQTRI*\<$C%?E
M_&W SX/P^1XF.;4\UI9S'-8N2PM/ 3P^)RK'U,'6IK"3S?,\94H.*IM8Z3JY
M=6Q2Q6%R_-,R^I8B5.:]+V,XPYE-N#DY1:<6XU9TFXV][V<G'FIRFH2J0:G%
M3IN-67SQ^SU_R>U^V7_V1[]C?_TL_::K[_KX _9Z_P"3VOVR_P#LCW[&_P#Z
M6?M-5]_U^"YA_OV+_P"O\_\ VP_J?A#_ ))?(?\ L64/_2L2? O[3_\ R=9^
MPM_V$/VD_P#U44%=Y\3?BIX3^$6@P>)/&5MXZN-)N+X:>&\!?"GXJ?%W4K:4
MV=W?-<ZAH7PD\%^.->TO28K:RN&N==U+3+71+67R+>YU"*YN[2*?@_VG_P#D
MZS]A;_L(?M)_^JB@KV;Q.DDGAKQ%'$DDLLFA:ND<42/)+)(^GW"I'''&&>21
MV(5$16=V(5020*^PX0>#Y\)_:&'K8O RS",,5AJ&->75JM&I.E2E&GCEA,>\
M+*+JQJ*K]3Q"2I.+I\M24Z?Y#XE1A/BW"4ZB;IU,#E].5I<EE4JU:?-S6=N3
MVG.T[)J'*Y1BW*/S]\/OVPOV>?BMI/A#6?"7BKQ/-X>^)6O^'/"7P\UWQ7\'
MOC1\/O#OQ&UCQEX>\2>)_#UIX#UOXB_#OPMI'C>RU;PYX3\0:J-5\,W>K:-!
M96<;7M];G4--6\]WT3P/X-\,Z/=^&O#?@[POX>\/W[737WA_0O#NDZ1HUZ]]
M"+>]:[TG3[.WL;EKRW @NFFMW-Q"!%,7C 6OQX\-_"'6?%G[#_\ P1\^'OC#
MP)XX>/0/B-^S>?B3X9_LWQGX?UCPSI6E_LT?&73M53QM!I0TO7/#6DVVJ75A
MHNO1:X^GV#3:A!H>KHPU$6=QYQXIT7XY:5::-X3UFSU2S_9:^'?[37[97A+4
M=!^)'A'X]^,O#8T&P\1> ;O]F>+5K'X97]O\4M>^'6DVUY\1H/ 6J?:-;\ 0
M:FGA^'48WN].\&7FG?U1B_![AK,<QS#+N%>-*V28?!\3\:8#$Y=G&:8;-(X_
M \(<=\6\(</8W+,7E^+RN&:<0YQ#AI8[!9=5R7ZM&IG-&ME.<?4HTZF/_/Z5
M#VL*52G4]G%PIUITXN;G3JU:^:4:2I7FW-QAE\9U:K=&I1C5<FIP=,_<NQ\"
M>"=-T>X\/Z;X+\*:?H%UI8T.[T.P\-Z/::-<Z*)+Z8:/<Z9;V4=C/I0EU/4Y
M1I\L#68DU&_?R=UY<&3S;XF_ #PM\1?"VF^%--UKQ-\*[/3;ZTO+:7X8V_@R
MSL;Z"STY=)@TGQ#X'\:>#?&_PN\::+!816D>FZ=XS\!>(8_#]UI^EZKX9;1=
M8TO3]0MORN^%/@+XS:U\7OA)J/Q7TCXW?$4?#[]BGXW>-?!$6J6?B_P!!+\0
M?#_[34&J? ;3I;;7_&'CK19OB3IGPT31=(\':K\9]7U[XEZSX=0>(?BEX>T[
M7=3\8Z!;?)7C[Q)\5O#OP5^./B7PP_Q)\-6/B3_@E+^W9XJ^-FIZ1X*_:&\(
M'P_^T5X3TGX2WW@)_&_Q,^*6I11^*OCOH6G:Q\0K2#Q#X:T#P-<W-Y'XEUK3
M[>32M0TK1_#7?P_X)YM6XBPN'R?Q4P,\TAB\CQ"S*-%X[+5F6=YSB<HP\G#'
M<0YG5QN(66JM4ISQV4NKB<TJQR&A*=9PQ*WHX2;J)4\1%M5*5/F?+*$O;PPO
MM7"F^=S4J6,IN%DG55*NYNG]7;C_ $1^#_@A\,?!'@SPKX$T[PCIFJ:'X/U?
M4_$VBOXJM8/%&J1^+]=UG5?$?B#QK+J>MPW=RWBW7_$6NZWKFJ:Y"T%U+J.K
M7SP&W@E6!.Z;PMX;-QI]TWAO0C=Z/:7]AI5RVC:>;G2K#551-4LM.F-MYMA:
M:DB1IJ%M:M##>JB+<I*%4#\/?B3I'Q:>+Q^W[&EO\2M(^!$V@?LX+\<5\<:1
M^T ^N:KXQB^-:2?&NZT/3]7N-.^*FN:U<?!,&#XU:C\-+^'5=;L)+%+#4]0\
M2QWR&;PFOQ3\'1?"'XE+J/C9_P!G/X;?MU>&/%MY8>!/AC\<]"\(^$_A#JG[
M'_Q7\!^)9/!_A7QCX@\8?&?QM\)7^-WBSP-?:G9:MX,T3PYX5\;W/B#4?#>F
MZEX:TF77M.\?$^#F99CA9YO7\3,-6Q^88C&58Y7F+QM//XYEF&69GF<\HSG
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M1OV>;#X-7^E^!/CO\0/$NB?'R/X?>*8OC#JW@:?X)>,O!?PWA^.K_$IK!_%
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MK^>S1/AS\9?AYX8TGP1^S=X0\9^"?C'I_P"VG_P5FUJ2U?1?&VG>$4\1^.?
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M,.HR:UX?D\.S6VN:Q86%O)JEAJIU/1[*^E@TK7UDT]GCLX];LUCOTTRY(O\
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MV$-JFC7RW"LUQ 59XS_:"^%WPU\5:YH/Q(^('PV\"Z?HFA?#W5)[_P 3>/\
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MR/?L;_\ I9^TU7W_ %\ ?L]?\GM?ME_]D>_8W_\ 2S]IJOO^O@\P_P!^Q?\
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M;2HTW4=2"IU&VI<LJE-1BJ=6=-4*E:FH05.M5KT^2G[/V=/[FKXI_P""<O\
MR8[^S3_V373_ /TNOZH#_@I]_P $TR0!_P %#OV&B20 !^UI\ R23P  /'^2
M2>@I_P#P34U'3M8_8-_9:U?1]0L-7TC5?A1HNI:5JVE7MMJ.EZIIM_->75CJ
M.FZC92SV=_I]]:RQ75E>VDTUK=VTL4]O+)%(CGP#I/N*BBB@ HHHH **** /
MSG^./_*2/]D+_LQG_@HI_P"M ?\ !+:OJ"O@[]LKXX_!/X!?\% OV-/%WQW^
M,?PI^"7A34_V,O\ @H;X<TSQ/\7OB+X.^&GA[4O$-U\<_P#@F-J=MH.GZUXU
MUG1--O=:N--TG5=0ATNVN9;Z6QTV_NT@-O9W$D>Y_P /*?\ @G+_ -) OV(/
M_$LO@%_\\"OK<EJTH8)*=2G%^VJNTIPB[/DL[.2=GZ'\^>)6!QN(XFE4H8/%
M5Z?]GX*//1PU>K#F4:]USTZ4XW5U=7NKJZU/LN^OK/3+&\U+4;F&RT_3K2XO
MK^\N'\NWM+.TA>XNKJ=SPD-O!')+*YX5$9CTK\U?$W[=.O76D?";3_#$/A#P
M+XS^,OPAU[]I'PY_PF7@7XI?%8Z1\&E\6^%=&\ 6.L_#+X3R6?Q*N/$_B_0_
M%UAKGCGQ-IT+^$O@C9:;XBU3Q);>)=,T8/?=YXQ_X* ?\$TO''A#Q7X*UK_@
MH#^Q*=&\8^&M=\*ZN+?]K;X"13G2_$.EW6D:@()%^((:.8VEY,(I 04?:P((
MKX7\ _M1_LEZ1I?P ^)VA_\ !1'_ ()U^#OVAOA%\ [O]E;QNWCO]H_X(>(_
M!/CCP=HNN^%3%XUT*/PK\8]'U;3DOM6\!Q^-_!=G/?['T3QG=Z)XHTZPU6T!
ML?VSP[J>'U+!X_'<53RS%8^CCJM'+L)F>/CALO4Y<,XW$9+/&\M''MY7BN)*
M6)P><8G^S,R6#C2R.%;"QPN.JXF'QN'RO&1C!U,NQG.ZE16J8'%RBN1X"45*
M*HIN$\++-))J.N*I86ESP<X'V'XK_:[^+=]!\0M4^''ASX06<7[/?[+_ ,-O
MVF/C1X;\2>)-3\='Q=/\2O#7Q%\66?PJ^&OQ"\!:II_A_P .1:9H?PRU.^M_
MC#J/A[XC:+XE7Q%H/]F?#^VLK>]U.;[.UKXO^"M ^$T?QHU*[OD\&7'A31_%
MMBMKI]Q?:]JT'B.TLKCPYH>B:':J]_K/BOQ)>:GINA^'O#FGQ3:GK?B'4;#1
MM/@FOKR")_Q*'C;]@[P#X.U;X;? [_@J1_P3RT+P=\0_V5/A?^R9\3[WX@_'
MWX+^)_%,7AKX5>'/'_@_1/B!X)N=&^,^@Z?_ ,)9=^&_B5KEI<Z%XHMM3\-6
M]UI'AN:T$5E!J>FZE].>+_VEO^"6OQ*T#PM\.O'O[?O['*_#;X5:EX UWX0+
M\._^"@.B_"/QYH>O^"O#.J>&H=1U_P 8?"SX]^"]2U2.SM=1)T;3H[I=,2?&
MI7]C<ZK8:3>67M<3S\&ZU3(893FF&HY-0SGGQN(RC!8FGQ+7X:IY9B(X^&99
M?CL:H3SG'<4K#5,FPZS>M7ROA;%5YK&XO^R*.#S*'E>,YJ#>6X]TX1J\R^HX
MKVE2'+A%A(UE"A&U:52.,ECI1FYTXU5&$ZO)AYGHG@+]L+XQ?%+X<? "#3OA
MWX2^&7QJ_:&^,O[1'PLM[?Q6VJ>/O ?P?MO@'J/Q<DU"]\5V?AK7_"E_\0?$
MMUIWPUL-%_X1OP[XP\):;?:YK&LZSI_BF/1?#:6FL<+XV_X*)^)])\/Q:EX6
M\%>$]3U3P%>_M01?%2TN+K6;VP\9ZG^RG\4O"'PH\3_#GX-7MI<V,L/CSXA7
MGC.S\6>%7UFW\3)X?L-,NO#6H:!X@O;M]=TOYC\.^./^"?O@#]GVR^#GA;_@
MIY^P3XXN;/X^?%+XU7]K\>OVL_!/Q>\,>);3X@>(_'^J:3X;&K^,/V@-<^)G
MP^U/PO;>+=&U ^+OAQXQT2\\0>)]$\1ZCK^G:C'\2?&?V[W+PS\?/^"7OA/X
M.2?#/2OV_/\ @GG%K=]\1O$_Q1E\5)\?OV;EB\*^,?B%XMO]9\:^(?AII-Q\
M0;P>#-?T[P[KNN^&O &M6UW/J7A_=IVH:A<ZM(NHQ:A]5B\[^C[@,PQ6*P^5
MY3G>6OB_'TLLR[#RS7+K9+B<TQ<JN8YA+,L9B\VHY1A,@Q.!R[)<IGB\?7IX
MS 8C/*>-K9_6^K1T_LS%QY+Y9C:D93Q496P6+A*$?:9ER5/W>&E.]2+P#H14
MD\/22A#GDZM6/Z(^ OC9X?\ B-XD^('A+0/%?P_7Q/HD3:EX2\(OXBT^[\;W
M/A!3-HEI\2O$7@^TU;^WH/A_XD\8V&L6G@[Q!;V5II?BC0=-CU?2-3N[?4[.
M<:_P&^+%M\:_A?HGCM+)-)U;^U/%_@WQEH,<ZW(\-?$;X9^,=>^''Q(\,B=7
M?SDT'QSX5U_3+>=FW7-I;V]UC$XK\G?"GQF_X)S^ _C[/\7;#_@I;^Q#-X!\
M/>,?&?Q5\(> =(_:=^"">*+;Q3XS^#7A#X*ZMX1GU1_BO_9.H> -)\+>!=)O
MO!V@6^DV5Y;:W<0VUS>-8Z/IYD]8_9-_;9_8&^%?P?:Q\9?M]_L.V7C?X@?$
MWXU_'+QII47[77P NH?#WB3X\?%WQI\6[SPI%<1>/8X9U\'P>+[7PK)<P)Y5
M[/H\UZKR_:3*_P"<<483PWH9)F&*X:SZGF&)G+@:KE].K"&%QN%Q.,P6?4^*
M\IKTG57UG#X'"X+)<RKXWV35#.\76P4,7BX8JA##95\JQJ35/ XZ4O;4^7EP
M&+7-2E@N>NVG034:.+5"E2DHQ]K*KB8N*]CSR_6JOD_X_?\ )P__  31_P"S
MV/'O_KMW_@H/7-?\/*?^"<O_ $D"_8@_\2R^ 7_SP*\<\3_M>_LE_'G]JO\
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M_2=1US6+Z0,T=EI>DV<U_J%W(J!G9+:TMYIG"*S%4(52<"OB#QU^TQ\2M%^
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M/*?^"<O_ $D"_8@_\2R^ 7_SP*]CV]#_ )_4O_!M/_Y,_.O[+S/_ *%N8?\
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MG09-)M=95-<74HH_-;C]L/Q;IVHZE\1=6T/PKIWP+T_]K31_V+E\-2V.L?\
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M ,&T_P#Y,C^R\S_Z%N8?^$6+_P#F<]._9Z_Y/:_;+_[(]^QO_P"EG[35??\
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M ),R_LO,_P#H6YA_X18O_P"9SV#]@[_D#?M1_P#9Z?Q^_P#2OP[7W;7YT_\
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MGV6K:3J-I(LUKJ&F:E;17EA>VTJ$K);W=K-%/#(I(>.16!P:T*_/WP#^WO\
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M-=V=DS^A&BBBOEC]Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
